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ABSTRACT 
 
LOSS OF SKI EXPRESSION IN TESTICULAR CANCER LEADS TO AN 
ENHANCED INVASIVE PHENOTYPE THROUGH BOTH BMP-DEPENDENT 
AND BMP-INDEPENDENT PATHWAYS 
 
 
by Amy N. Nash 
 
 
The proto-oncogene SKI is a transcription factor and a co-repressor of the TGFβ 
superfamily, including TGFβ and BMP.  However, additional data suggests that SKI may 
function as a tumor suppressor in some cell types.  The TGFβ superfamily has been 
implicated in cancer progression and germ cell migration.  Testicular cancer afflicts men 
during their peak reproductive years and is the most common cancer among men of this 
age group.  Cisplatin-based chemotherapy is the standard treatment for testicular cancer.  
This treatment can lead to undesirable side effects, including infertility.  We have shown 
that SKI expression is decreased in testicular germ cell tumors compared to normal 
testis.  The hypothesis of this work is that decreased SKI expression promotes testicular 
cancer progression by allowing unregulated TGFβ superfamily signaling, conferring an 
increased ability of testicular cancer cells to invade and metastasize.  To test the effects 
of decreased SKI in testicular cancer, we used a human embryonal carcinoma cell line, 
NCCIT.  We found that transient SKI-knockdown confers an increased ability to migrate 
and invade, but does not affect proliferation, in NCCIT cells.  Forced overexpression of 
SKI in NCCIT cells resulted in decreased migration and invasion compared to control 
cells.  We next investigated whether TGFβ or BMP enhanced the invasive phenotype of 
stable SKI-knockdown NCCIT cells.  NCCIT cells stably transfected with nonspecific 
shRNA were used as a control.  Addition of TGFβ or TGFβ blocking antibody had no 
effect on the migration of either SKI-knockdown cells or control cells.  Addition of BMP4 
enhanced migration in SKI-deficient NCCIT cells but had no effect on control cells.  
Treatment with noggin, a BMP inhibitor, reduced the migration of SKI-deficient NCCIT 
cells back to the level of control cells.  These data imply that in NCCIT cells with 
decreased SKI expression, the BMP pathway, but not the TGFβ pathway, promotes 
migration.  Microarray analysis was performed to identify downstream targets of SKI that 
may be involved in cellular invasion.  CXCR4 expression was increased in SKI-
knockdown cells compared to control cells, but CXCR4 expression was not affected by 
treatment with BMP.  Signaling partners CXCR4 and SDF1 have been implicated in 
germ cell migration and cancer metastasis.  Addition of SDF1 enhanced the invasive 
potential of SKI-deficient cells but had no effect on control cells.  Addition of AMD3100, a 
potent and specific inhibitor of CXCR4, blocked the effects seen with SDF1.  These data, 
taken together with the BMP data, imply that decreased SKI expression in NCCIT cells 
leads to enhanced invasion through both BMP-dependent and BMP-independent 
mechanisms.  This research provides insight into the mechanism behind testicular 
cancer metastasis, and it identifies the BMP signaling pathway and CXCR4/SDF1 as 
potential targets for the development of new therapies to treat patients with metastatic 
testicular cancer. 
 
 
DEDICATION 
This work is dedicated to my husband, Jordan.  His constant support, love, 
and encouragement have kept me going during the pursuit of my Ph.D.   
 iii
 ACKNOWLEDGEMENTS 
  
I would like to express my sincere gratitude to my mentor and advisor, Dr. 
Laura Richardson.  I appreciate her guidance and belief in my abilities as a 
graduate student.  I would also like to thank the other members of my committee, 
Drs. Delidow, Hardman, Kiningham, and Primerano for their guidance and for 
their roles in my education.   
 
Thanks to the other members of the Richardson lab, Rachel Johnson and 
Aslam Chaudry, for technical help, enduring my moments of insanity, and for 
helping maintain an efficient lab. 
 
Thank you to Dr. Goran Boskovic for microarray analysis and to Drs. Jim 
Denver and Yulia Dementieva for performing and explaining the statistical 
analysis on the microarray data. 
 
Finally, thank you to my friends and family for your invaluable support, 
encouragement, and patience. 
 iv
 TABLE OF CONTENTS 
 
ABSTRACT.........................................................................................ii 
DEDICATION.....................................................................................iii 
ACKNOWLEDGEMENTS..................................................................iv 
TABLE OF CONTENTS......................................................................v 
LIST OF TABLES.............................................................................vii 
LIST OF FIGURES...........................................................................viii 
LIST OF SYMBOLS, ABBREVIATIONS...........................................ix 
CHAPTER I.........................................................................................1 
INTRODUCTION..............................................................................................1 
 Purpose of the Research..........................................................................2 
 Significance of the Research...................................................................3 
CHAPTER II........................................................................................4 
REVIEW OF THE LITERATURE.....................................................................4 
 Male Germ Cell Development...................................................................4 
 Primordial Germ Cell Migration...............................................................5 
 Overview of Spermatogenesis.................................................................6 
 Intratubular Germ Cell Neoplasia............................................................7
 Testicular Germ Cell Tumor Classifications...........................................7 
 Risk Factors Associated with Testicular Cancer.................................11 
 Molecular basis of testicular cancer.....................................................12 
 Treatment for Testicular Cancer............................................................17 
 Testicular Cancer Metastasis.................................................................21 
 TGFβ Superfamily...................................................................................22 
 SKI............................................................................................................33 
Hypothesis....................................................................................................35 
CHAPTER III.....................................................................................36 
RESULTS.......................................................................................................36 
 SKI expression is decreased in TGCTs compared to normal testis..36
 SKI expression varies among different human cell types..................38 
 Manipulation of SKI expression in NCCIT cells...................................39 
 Effects of SKI on migration in NCCIT cells...........................................41 
 Effects of SKI on invasion in NCCIT cells.............................................43 
 SKI expression does not affect the growth rate of NCCIT cells.........46 
 Effect of TGFβ on cell migration in SKI-knockdown cells..................49 
 Effect of BMP on cell migration in SKI-knockdown cells....................52 
 SKI Expression in shNC and shSKI NCCIT cells treated with BMP  
and/or Noggin..........................................................................................57 
Microarray Analysis................................................................................57 
 v
SDF/CXCR4:  Role in invasion of SKI-knockdown cells......................79 
CHAPTER IV.....................................................................................84 
DISCUSSION.................................................................................................84 
 Summary................................................................................................110 
Future Directions..................................................................................113 
CHAPTER V....................................................................................116 
METHODS....................................................................................................116 
 Tumors...................................................................................................116 
 Laser Capture Microdissection............................................................116 
 Cell Culture............................................................................................117 
 Materials.................................................................................................117 
 Transient siRNA Transfections............................................................117 
 Flow Cytometry.....................................................................................118 
 SKI Expression Vector Transient Transfection of NCCIT Cells........118 
 Generation of Stably Transfected SKI-knockdown NCCIT cells.......119 
 Real Time PCR.......................................................................................121 
 Western Blotting...................................................................................121 
 Cell Scrape Migration Assays..............................................................123 
 Matrigel Invasion Assays.....................................................................124 
 Microarray Gene Analysis....................................................................125 
 Statistical Analysis...............................................................................126 
BIBLIOGRAPHY.............................................................................129 
CURRICULUM VITAE.....................................................................158 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
   
 
 vi
 
LIST OF TABLES 
 
Table 2.1. TNM Staging System for Testicular Germ Cell Tumors................20 
Table 3.1.  Gene Sets Enriched in shSKI NCCIT Cells Identified by 
GSEA...................................................................................................................64 
Table 3.2.  Regulation of MAP Kinase Activity Genes Upregulated in shSKI 
NCCIT Cells........................................................................................................68 
Table 3.3.  Transforming Growth Factor Beta Receptor Signaling Pathway 
Genes Upregulated in shSKI NCCIT Cells.......................................................69 
Table 3.4.  WNT signaling family genes identified by microarray analysis..71 
Table 3.5.  Chemokine genes identified by microarray analysis...................72 
Table 3.6. TGFβ superfamily signaling genes identified by microarray 
analysis...............................................................................................................72 
Table 3.7.  SMAD Promoter Elements in Potential Target Genes..................78 
 
 
 
 vii
 
LIST OF FIGURES 
 
 
Figure 2.1.  Normal germ cell development vs. germ cell tumorigenesis......9 
Figure 2.2.  TGFβ superfamily signaling cascade..........................................26 
Figure 3.1. Decreased SKI expression in human testicular germ cell 
tumors.................................................................................................................37 
Figure 3.2.  SKI Expression in Human Cell Lines...........................................40 
Figure 3.3.  siRNA Knockdown and Forced Expression of SKI in NCCIT 
Cells....................................................................................................................42 
Figure 3.4.  Cell Scrape Migration Assay on NCCIT Cells..............................44 
Figure 3.5.  Matrigel Invasion Assay on NCCIT cells......................................47 
Figure 3.6. Cell Growth Measured by Trypan Blue Cell Counts....................48 
Figure 3.7.  SKI knockdown in shSKI NCCIT cells..........................................50 
Figure 3.8.  Effect of TGFβ on the migration of shNC and shSKI NCCIT 
cells.....................................................................................................................51 
Figure 3.9.  Induction of SMAD2 phosphorylation by TGFβ in shNCCIT 
cells.....................................................................................................................53 
Figure 3.10.  Effect of BMP on migration of shNC and shSKI NCCIT cells..55 
Figure 3.11.  Phosphorylation of SMAD1/5/8 by BMP4..................................56 
Figure 3.12.  SKI mRNA expression in shNCCIT cells treated with BMP 
and/or noggin.....................................................................................................58 
Figure 3.13.  LEFTY1 and ADAMTS-1 expression in shSKI NCCIT cells 
compared to shNC NCCIT cells........................................................................73 
Figure 3.14.  CXCR4 mRNA expression in shNCCIT cells treated with BMP 
and/or noggin.....................................................................................................81 
Figure 3.15.  SDF1 mRNA expression in shNCCIT cells treated with BMP 
and/or noggin.....................................................................................................82 
Figure 3.16.  Role of CXCR4/SDF1 in the invasive potential of shNCCIT 
cells.....................................................................................................................83 
Figure 4.1.  Proposed mechanism for SKI’s role in testicular 
tumorigenesis..................................................................................................109 
Figure 5.1.  Transfection efficiency assessed by Block-It transfection......120   
 viii
 ix
LIST OF SYMBOLS, ABBREVIATIONS 
 
 
AJCC – American Joint Committee on Cancer 
BMP – Bone morphogenetic protein 
CCND – cyclin D 
ECM – Extracellular matrix 
ELR - glutamic acid-leucine-arginine 
EMT – epithelial to mesenchymal transition 
FBS – fetal bovine serum 
GCT – germ cell tumor 
GSEA – gene set enrichment analysis 
HRP – Horseradish peroxidase 
ITGCN – Intratubular germ cell neoplasia 
NER – nucleotide excision repair 
OMIM – Online Mendelian Inheritance in Man 
PBS – phosphate buffered saline 
PGC – Primordial germ cell 
Rb – retinoblastoma 
SCF – Stem cell factor 
SDF1 – Stromal derived factor-1 
TGFβ – Transforming growth factor β 
TGCT – Testicular germ cell tumor 
 
 
 CHAPTER I 
INTRODUCTION 
 
Testicular cancer is the most common cancer in American males between 
the ages of 18 and 35; however, the molecular mechanisms involved in the 
development and progression of testicular cancer are poorly understood.  In 
recent decades, the incidence of testicular germ cell tumors (TGCTs) has 
increased annually at a rate of 3 - 6 percent in Caucasian populations (Ulbright, 
1993).  The precursor lesions to testicular cancer, termed intratubular germ cell 
neoplasia (ITGCN), are thought to arise from primitive germ cells that have 
evaded normal differentiation.  There are three categories of testicular germ cell 
tumors; Type II is the most prevalent type and, therefore, the most widely studied 
and will be the main focus of this thesis.   
Cancer is a multi-step disease, typically involving alterations in multiple 
signaling pathways that eventually lead to cellular transformation.  Several genes 
have been identified that may be involved in the development and progression of 
testicular cancer.  However, very few studies have been performed to identify the 
mechanism by which these genes promote testicular tumorigenesis. 
The proto-oncogene SKI is a transcription factor that can function as a co-
repressor of the transforming growth factor β (TGFβ) superfamily, including 
TGFβ and bone morphogenetic protein (BMP), by binding to SMADs, the 
downstream signaling molecules of TGFβ and BMP.  The TGFβ superfamily has 
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been implicated in cancer growth and metastasis as well as germ cell migration 
during development, making them of particular interest in testicular cancer 
research.  The role of the TGFβ superfamily in cancer is complicated, with 
several studies suggesting that TGFβ and BMP may have both tumor suppressor 
and tumor promoting functions, which may depend on both cell type and the 
stage of cancer progression.  Similarly, the role of SKI in cancer is still 
incompletely defined and may also be tissue-dependent.  Some tumors express 
high levels of SKI, however, loss of SKI function has been linked to 
tumorigenesis in mice heterozygous for a null mutation in the SKI gene, 
suggesting SKI may also function as a tumor suppressor. 
 
Purpose of the Research  
 The objective of the following body of research is to determine the role 
that SKI, which we have found to be decreased in testicular tumor samples 
compared to normal testis, plays in testicular cancer.  SKI was originally 
identified as an oncogene based on its ability to transform avian fibroblasts 
(Stavnezer 1981, Colmenares 1989); however, other data has provided evidence 
that SKI may have tumor suppressor activities (Shinagawa 2001).  The purpose 
of the following research is 1) to identify the role of SKI in testicular cancer 
progression using biological assays; 2) to determine how upstream signals from 
the TGFβ superfamily contribute to the effects of decreased SKI in testicular 
cancer; and 3) to identify downstream target genes of SKI that may also 
contribute to testicular cancer progression.   
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Significance of the Research 
The data presented in this text addresses an area that is lacking in 
testicular cancer research by studying the mechanism by which SKI contributes 
to the progression of testicular cancer.  Furthermore, this research has been 
focused on testicular cancer metastasis, an area of testicular cancer that has not 
been widely researched.  The TGFβ superfamily and SKI have previously been 
reported to play conflicting roles in tumorigenesis, apparently depending on the 
stage of cancer progression and tissue type; thus, we have sought to define the 
specific role that SKI and TGFβ superfamily members play in testicular 
tumorigenesis.   
This research is significant, not only because it fills a gap in the research, 
but also because it will allow a better understanding of testicular cancer 
progression.  This has been accomplished by investigating SKI and its potential 
role as a tumor suppressor of testicular cancer and also by considering the 
upstream and downstream signals of SKI that contribute to the overall 
mechanism of testicular cancer progression.   By providing further insight into 
testicular cancer progression, this research may contribute to the development of 
more efficient treatments that better preserve male fertility and provide a better 
quality of life for patients afflicted with the disease. 
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 CHAPTER II 
LITERATURE REVIEW 
 
Male Germ Cell Development 
Very early in mammalian embryonic development, a distinct cell 
population arises that has the ability to transmit genetic information from one 
generation to the next.  These pluripotent cells are primordial germ cells (PGCs), 
the fetal precursors to sperm and oocytes, and they are derived from the 
proximal epiblasts in response to signals from the extraembryonic ectoderm 
(Lawson, et al., 1999; Lawson and Hage, 1994).  In the mouse, the specification 
of a population of about 45 cells to the germ cell lineage occurs at approximately 
embryonic day 7.2; at this time the cell cluster is located in the extraembryonic 
mesoderm (Lawson and Hage, 1994).  Lawson, et. al. (1999) showed that BMP4, 
secreted first from the extraembryonic ectoderm, and later from the 
extraembryonic mesoderm, is required for the allocation of the PGC population.  
BMP8b is also expressed by the extraembryonic ectoderm, and appears to act 
synergistically with BMP4 in the generation of PGCs (Ying, et al., 2000; Ying, et 
al., 2001).  These cells can be identified by staining for alkaline phosphatase, 
which continues to be expressed in these cells during their migratory phase 
(Ginsburg, et al., 1990).   
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Primordial Germ Cell Migration 
During embryonic development, PGCs migrate through the primitive 
streak, into the allantois, and then enter the embryonic endoderm, which gives 
rise to the hindgut (Anderson, et al., 2000).  In the mouse, PGCs migrate through 
the hindgut and come to rest in the genital ridge at around embryonic day 11.5 
(Anderson, et al., 2000).  The migration of the PGCs is dependent upon 
interaction with the extracellular matrix (ECM) and specific signals secreted from 
the genital ridge.  There are several factors associated with the ECM that 
influence PCG migration.  Fibronectin, an adhesive glycoprotein found in the 
ECM, stimulates the migration of PGCs from the hindgut (Ffrench-Constant, et al., 
1991).  In the mouse, PGCs lacking β1-integrin, which is involved in cell-ECM 
attachment and cell migration, have a reduced ability to colonize the gonad 
(Anderson, et al., 1999).  During migration, PCGs associate with one another via 
cytoplasmic processes.  E-cadherin appears to play a role in this connection as it 
is upregulated in PGCs when they are leaving the hindgut, and blocking E-
cadherin prevented PGC aggregation by preventing their formation of tight 
clusters in the genital ridges in vitro (Bendel-Stenzel, et al., 2000).  The genital 
ridge also secretes factors that influence the direction of PGC migration in vitro, 
and TGFβ has been shown to act as a chemoattractant of PGCs in culture, 
indicating that it may be one of the factors secreted by the genital ridge (Godin 
and Wylie, 1991).  The ligand stem cell factor (SCF) and its receptor, c-kit, are 
required for PGC survival, migration, and colonization of the hindgut (Besmer, et 
al., 1993; Buehr and McLaren, 1993).  PGCs express c-kit, and cells of the 
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hindgut express SCF (Besmer, et al., 1993).  Signaling partners, stromal derived 
factor-1 (SDF1) and its receptor, CXCR4, are also required for PGC migration 
and survival (Molyneaux, et al., 2003; Stebler, et al., 2004).  Migrating PGCs 
express CXCR4, and SDF is expressed in the genital ridges (Molyneaux, et al., 
2003).  PGCs with mutations in CXCR4 do not colonize the gonad normally 
(Stebler, et al., 2004).  BMP may also be involved in regulating PGC motility.  
PGCs express BMP receptors, and BMP4 increased PGC numbers, while noggin, 
a BMP inhibitor, reduced PGC numbers and slowed their migration.  Furthermore, 
BMPs induced, and noggin suppressed, the expression of SCF in the genital 
ridges (Dudley, et al., 2007).   
 
Overview of Spermatogenesis 
Once the PGCs enter the genital ridges, they are no longer migratory, and 
they are termed gonocytes.  Before birth, the gonocytes undergo a few rounds of 
mitosis before entering a period of mitotic arrest as prospermatogonia (McLaren, 
2003).  Spermatogenesis begins at puberty with type A spermatogonia, which 
are capable of self-renewal to maintain the germ cell population throughout life.  
These cells divide asymmetrically to form type A and type B spermatogonia, the 
precursors of the spermatocytes.  Type B spermatogonia undergo differentiation 
to form primary spermatocytes.  Primary spermatocytes enter meiosis I, followed 
by spermatocytes undergoing meiosis II to form spermatids (Figure 2.1).  
Spermatids then undergo a differentiation process to form mature spermatozoa.  
Spermatogenesis is a complicated process that is dependent on specific signals, 
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many of which come from Sertoli cells, which provide nutrients and growth 
factors to the maturing germ cells (Puglisi, et al., 2004).   
 
Intratubular Germ Cell Neoplasia    
While there are distinct groups of testicular cancer with histological 
differences, all are believed to be of germ cell origin (Figure 2.1).  TGCTs arise 
from precursor lesions, known as intratubular germ cell neoplasia (ITGCN) (also 
referred to as carcinoma in situ), which are thought to arise from primitive germ 
cells that have evaded normal differentiation (Chaganti and Houldsworth, 2000; 
Oosterhuis and Looijenga, 2005).  ITGCNs, PGCs, and gonocytes have similar 
morphologies and some similar patterns of gene expression, including positive 
staining for alkaline phosphatase and c-kit expression (Kristensen, et al., 2008).   
 
Testicular Germ Cell Tumor Classifications 
Testicular germ cell tumors (TGCTs) have been divided into three 
classifications based on epidemiology, their histology, and the age group in 
which they occur:  Type I – teratomas and yolk sac tumors of newborns and 
infants; Type II - seminomatous and non-seminomatous tumors of adolescents 
and young adults; and Type III – spermatocytic seminomas of the elderly 
(Oosterhuis and Looijenga, 2005).  Of these three groups, Type II TGCTs are the 
most common and account for approximately 60% of malignancies diagnosed in 
men between the ages of 20 – 40 years old (Oosterhuis and Looijenga, 2005; 
Ulbright, 1993), also making testicular cancer the most prevalent cancer among 
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men of this age group (Chaganti and Houldsworth, 2000).  Type I pediatric GCTs 
are rarer, constituting about 3% of childhood tumors (Bussey, et al., 1999).  In 
addition to the testis, type I GCTs can be found in sacrocoxygeal region, head 
and neck, and midline of the brain (Looijenga, et al., 2007).  Type III TGCTs are 
the rarest type, occurring predominantly as benign tumors in males over 50 years 
of age (Oosterhuis and Looijenga, 2005).  Type III tumors are found primarily in 
the testis and rarely metastasize (Looijenga, et al., 2007).   
Type II TGCTs consist of seminomas and embryonal carcinomas (also referred 
to as nonseminomas) (Figure 2.1).  Of these seminomas are the most common 
type, comprising about 50% of TGCT (Bahrami, et al., 2007).  Seminomas are 
rarely seen in pre-pubertal males; they most typically occur in men between the 
ages of 34 and 45 (Bahrami, et al., 2007).  Seminomas are morphologically  
similar to spermatogonial germ cells and generally respond very well to radiation 
and chemotherapy (Chaganti and Houldsworth, 2000).  Embryonal carcinomas 
also encompass tumor types with varying degrees of differentiation, including 
teratomas, yolk sack tumors, and choriocarcinomas.  Embryonal carcinomas 
occur most frequently in men between the ages of 25 and 35 (Bahrami, et al., 
2007).  Embryonal carcinomas are comprised of undifferentiated pluripotent stem 
cells (Looijenga and Oosterhuis, 1999).  Yolk sac tumors and choriocarcinomas 
exhibit extraembryonic differentiation patterns (Chaganti and Houldsworth, 2000).  
Teratomas display the most complete differentiation and are comprised of a 
variety of somatic tissues (Chaganti and Houldsworth, 2000). 
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Figure 2.1.  Normal germ cell development vs. germ cell tumorigenesis.  Normal 
germ cell development (left) begins during embryogenesis with primordial germ cells, 
which are allocated in the extraembryonic mesoderm and migrate to the genital ridge, 
where they are termed gonocytes.  Gonocytes undergo a few rounds of mitosis and then 
enter mitotic arrest as prospermatogonia before birth.  These cells divide asymmetrically 
to form type A and type B spermatogonia.  Type B spermatogonia undergo 
differentiation, forming primary spermatocytes.  Primary spermatocytes enter meiosis I, 
and then spermatocytes undergo meiosis II, forming spermatids.  Spermatids undergo a 
differentiation process to form spermatozoa.  Testicular tumorigenesis (right) is thought 
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to begin during embryonic development with the transformation with a primitive germ cell, 
possibly the primordial germ cell or the gonocyte.   Testicular germ cell tumors arise 
from intratubular germ cell neoplasia, most commonly during peak reproductive years.  
Testicular germ cell tumors consist of seminomas and embryonal carcinomas.  
Embryonal carcinomas also encompass tumors with various levels of differentiation, 
including teratomas, yolk sac tumors, and choriocarcinomas (adapted from Kristensen, 
et al., 2008). 
 10
Risk Factors Associated with Testicular Cancer 
There are several risk factors associated with the development of TGCTs, 
including both environmental and genetic influences.  Testicular cancer generally 
occurs at an earlier stage of life than many other types of cancer, thus it is 
thought that tumorigenesis may begin during fetal life.  It has been proposed that 
hormone levels in utero may have some effect on the development of TGCTs.   
TGCTs are much more common in Caucasian men than black men, and it has 
been suggested that this may be due to higher levels of testosterone during 
pregnancy in black women compared to Caucasian women (Looijenga and 
Oosterhuis, 1999).  There appears to be a genetic component to the 
development of TGCTs.  TGCT patients with an affected family member 
generally develop TGCTs at a younger age and are more likely to have bilateral 
disease (Looijenga and Oosterhuis, 1999).  Skakkebaek et. al. (2001) proposed 
a theory of testicular dysgenesis syndrome, which includes embryonic exposure 
to endogenous or environmental factors that affect gonadal development.  Risk 
factors associated with testicular dysgenesis syndrome and the development of 
testicular cancer include cryptorchidism, poor semen quality, Klinefelter’s 
syndrome, prior history of a GCT, and family history of GCTs (Chaganti and 
Houldsworth, 2000; Oosterhuis and Looijenga, 2005; Skakkebaek, 2004).   
 
Molecular basis of testicular cancer 
Most TGCTs display a high degree of aneuploidy.  Although various 
regions of chromosomal imbalance have been linked to the development of 
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testicular germ cell tumors (TGCTs) using microarray and FISH analysis (Korkola, 
et al., 2006; McIntyre, et al., 2004; Summersgill, et al., 2001; Zahn, et al., 2006), 
little is known about how these chromosomal regions contribute to tumorigenesis 
in male germ cells.  The most common chromosomal aberration associated with 
TGCTs is the occurrence of isochromosome 12p (Chaganti and Houldsworth, 
2000; Summersgill, et al., 2001).  However, various other chromosomal 
alterations are correlated with TGCTs (McIntyre, et al., 2004), including a 
frequently observed deletion in the short arm of chromosome 1, where the SKI 
gene is located.   Chromosome location 1p36 often contains deletions in 
testicular cancer samples and is a candidate region for tumor suppressor genes 
of testicular cancer (Zahn, et al., 2006).  While several studies have looked at 
expression profiles in TGCTs in order to identify possible oncogenes and tumor 
suppressors involved in testicular cancer, the field is lacking in studies of the 
mechanisms of particular genes to discover the specific role they might play in 
testicular tumorigenesis.  However, the following review of the literature provides 
a brief discussion of genes that have been more thoroughly investigated in 
testicular cancer research and have been presented as potential tumor 
suppressor genes and oncogenes based primarily on their expression pattern 
and previously known functions. 
 
OCT3/4 
OCT3/4 is a transcription factor that functions to maintain pluripotency and 
promotes survival in embryonic stem cells and primordial germ cells (Gidekel, et 
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al., 2003; Nichols, 1998; Pesce and Scholer, 2001).  OCT3/4 is expressed in 
PGCs of the human testis, and its expression gradually decreases with 
differentiation into spermatogonia (Rajpert-De Meyts, et al., 2004).  This gene is 
expressed in germ cell tumors with greater differentiation potential, such as 
seminomas and embryonal carcinomas, and has been identified through 
immunohistochemistry and microarray studies as a diagnostic marker for ITGCN 
(Almstrup, et al., 2007; Cheng, et al., 2007; Oosterhuis and Looijenga, 2005).  
While OCT3/4 is useful as a marker for both ITGCN and for identifying metastatic 
tumors of unknown origin, it is unknown whether OCT3/4 plays a causal role in 
testicular cancer or if it merely reflects the origin and developmental potential of 
TGCTs. 
 
CCND2  
Nearly all invasive type II TGCTs are positive for overexpression of 
chromosome 12p, most commonly due to the presence of one or more copies of 
isochromosome 12p (Oosterhuis and Looijenga, 2005).  This makes the 12p 
region popular for studying potential oncogenes of testicular cancer.  One such 
gene is cyclin D2 (CCND2), which maps to 12p13, and has been shown through 
both immunohistochemistry and RNA studies to be overexpressed in ITGCN and 
in most TGCTs (Bartkova, et al., 1999; Houldsworth, et al., 1997; Schmidt and 
Fan, 2001).  Houldsworth, et. al. (1997) found that CCND2 mRNA and protein 
were deregulated in a panel of germ cell tumor (GCT) cell lines and was 
aberrantly expressed in all ITGCN studied.  Furthermore, CCND2 was more 
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highly expressed in GCTs with a less differentiated phenotype.  CCND2 was 
present in all ITGCNs but was not expressed in normal germ cells.  These data 
suggest that CCND2 overexpression is an early event in male germ cell 
tumorigenesis. It has been suggested that increased expression of CCND2 may 
promote cell cycle progression by driving the cell through the G1 checkpoint, 
which may confer genomic instability (Houldsworth, et al., 1997).   
 
c-KIT/SCF  
The aberrant expression of chromosome 12p due to isochromosome 12p 
in TGCTs can result in an under-representation of chromosome 12q, making 
chromosome 12q a candidate region for tumor suppressor genes.  Murty et. al. 
(1992) evaluated 45 TGCT DNA samples with allelic loss at 12q and identified a 
high frequency of loss of heterozygosity at 12q13 and 12q22.  This group 
identified stem cell factor (SCF, also known as MGF), a ligand signaling partner 
for KIT, to be located within these chromosomal regions.  KIT is expressed in the 
primordial germ cells (PGC) during embryogenesis and in proliferating 
spermatogonia in the post-natal and adult testis; SCF is secreted from Sertoli 
cells (Devouassoux-Shisheboran, et al., 2003).  KIT and SCF are regulators of 
spermatogenesis; they are involved in PGC migration, cell adhesion, proliferation, 
and cell survival (Devouassoux-Shisheboran, et al., 2003).  In addition to 
decreased expression of SCF, KIT has also been shown to be over-expressed in 
some types of TGCTs, especially seminomas (Looijenga, et al., 2003).   McIntyre 
et. al. (2004) identified an amplification of 4q12, the region in which KIT is 
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encoded, and other activating mutations of KIT have been identified (Kemmer, et 
al., 2004; Looijenga, et al., 2003; Sakuma, et al., 2003).  These activating 
mutations have primarily been observed in seminomas as well as ITGCNs and 
are absent in non-seminomas (Devouassoux-Shisheboran, et al., 2003; Kemmer, 
et al., 2004).  KIT and SCF are known to play important roles in spermatogenesis; 
however, their function in TGC tumorigenesis has not been fully investigated.   
 
Rb 
Another potential tumor suppressor gene of testicular cancer is 
retinoblastoma (Rb).  While the more differentiated cells of teratocarcinomas and 
mixed tumors retain some expression of Rb, Rb mRNA and protein expression is 
undetectable in undifferentiated TGCTs, however no mutations in Rb have been 
observed at the DNA level (Strohmeyer, et al., 1991).  Rb is expressed during 
adult male spermatogenesis, but its expression is absent in PGCs, the precursor 
cells for TGCTs, and it is also absent in ITGCNs and most seminomas and 
embryonal carcinomas (Bartkova, et al., 2003).  Since no mutations have been 
detected in the DNA sequence of Rb, Bartkova et. al. (2003) suggested that the 
lack of expression of Rb in TGCTs may be a reflection of its developmental 
control and the cell of origin for TGCTs rather than a tumorigenesis promoting 
event.   
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GDF3 
GDF3 is another candidate oncogene for testicular cancer as it has been 
shown to be overexpressed specifically in embryonal carcinomas (Caricasole, et 
al., 1998; Clark, et al., 2004; Korkola, et al., 2006; Skotheim, et al., 2005).  GDF3 
is a TGFβ superfamily member with stem cell specific expression (Caricasole, et 
al., 1998).  GDF3 expression is low in seminomas but is abundantly expressed in 
non-seminomas, especially within embryonal carcinomas and yolk sac 
components of tumors.  Interestingly, GDF3 maps to the short arm of human 
chromosome 12, which, as previously mentioned, is regularly overexpressed in 
TGCTs (Caricasole, et al., 1998).   
While all TGCTs are thought to arise from a common precursor, ITGCN, 
the different tumor types appear to differ in their gene expression profiles.  This 
would suggest that different types of mutations may predispose the ITGCN 
toward the development of a seminomatous tumor over an embryonal carcinoma 
or vice versa.  Over-representation of chromosome 12p occurs in most ITGCN 
and is also common to the various types of TGCTs, further indicating that this 
may be a very early event in testicular germ cell tumorigenesis.  KIT, on the other 
hand, seems to be overexpressed primarily in seminomas and ITGCNs, while 
GDF3 is overexpressed in embryonal carcinomas. 
Through various other expression based profiles, several other genes 
have been identified as possible tumor suppressors or oncogenes of testicular 
cancer (Korkola, et al., 2006; McIntyre, et al., 2004; Oosterhuis and Looijenga, 
2005; Rodriguez, et al., 2003; Skotheim, et al., 2005; Sugimura, et al., 2004).  
 16
These genes have primarily been identified based on differential expression, and 
mutations have been identified in some.  However, there is a lack of research 
investigating the mechanism by which possible tumor suppressor and oncogenes 
may contribute to testicular tumorigenesis.   
 
Treatment for Testicular Cancer 
In 1970, metastatic TGCTs claimed the lives of 95 percent of men afflicted, 
however, cisplatin-based combination chemotherapy is effective in ablating 
TGCTs in more than 80 percent of men with metastatic germ cell tumors 
(Masters and Koberle, 2003).  The TNM staging system is the most commonly 
used method for determining the clinical stage of a testicular germ cell tumor 
(AJCC).  This system takes into account the size of the primary tumor (T), 
involvement of pelvic and abdominal lymph nodes (N), and metastasis (M) of the 
cancer to distant sites (Table 2.1).  Additionally, the patient’s serum (S) marker 
levels are considered.  Men with stage I disease have tumors that are confined to 
the testis with no evidence of metastasis.  A diagnosis of stage II involves 
metastasis to the lymph nodes in the abdomen or pelvis, and stage III refers to 
cancer that has spread to more distant lymph nodes in the chest, lungs, liver or 
brain.  High blood marker levels may also result in the diagnosis of stage III.  The 
serum markers that are evaluated for TNM staging include lactate 
dehydrogenase, human chorionic gonadotropin, and alpha-fetoprotein (AJCC).  
The standard treatment for TGCTs is combination chemotherapy, containing 
bleomycin, etoposide, and cisplatin, followed by surgical resection of the 
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remaining tumor (Dearnaley, et al., 2001; Droz and Rivoire, 2001).  Stage I 
TGCTs, those that are confined to the testis at the time of diagnosis, can usually 
be cured surgically (Masters and Koberle, 2003).  However, the more 
differentiated teratomas are more resistant to chemotherapy (Masters and 
Koberle, 2003).   
TGCTs are more sensitive to chemotherapy than other types of cancer.  
This sensitivity to cisplatin-based chemotherapy may be due to defective DNA 
repair mechanisms.  TGCTs have been shown to be deficient in nucleotide 
excision repair (NER).  Specifically they have decreased levels of some NER 
proteins, including XPA and ERCC1-XPF proteins, and adding these proteins to 
testis tumor extracts restored NER activity to normal levels (Koberle, et al., 1999).  
However, forcing the expression of XPA in human testis tumors cells did not 
confer an increased resistance to cisplatin (Koberle, et al., 2008), indicating that 
other genes, and possibly other DNA repair pathways, are likely involved in 
cisplatin sensitivity seen in TGCTs.   
While cisplatin-based chemotherapy has proven to be exceedingly successful in 
the treatment of patients with testicular germ cell tumors, patients who relapse 
after treatment with cisplatin-based chemotherapy have a poor prognosis.  
Patients with metastases, especially those with late relapse disease, defined as 
tumor recurrence more than two years after successful treatment without the 
presence of a contralateral tumor, have a worse prognosis (Sharp, et al., 2008).  
The tumors in patients with late relapse are more resistant to chemotherapy 
(Sharp, et al., 2008).  About ten percent of testicular cancer patients are either 
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unresponsive to chemotherapy or relapse after treatment (Mayer, et al., 2003).  
These patients are typically treated with intensive chemotherapy, surgical 
resection, and, possibly, radiotherapy (Dearnaley, et al., 2001).  This more 
extensive treatment is effective in about 30% of patients (Dearnaley, et al., 2001).   
Though the treatments for testicular cancer described above are highly 
effective, they are not without side-effects.  The more common side effects of 
chemotherapy, also seen in treatment of testicular cancer, include nausea, 
vomiting, alopecia, fatigue, neutropenia, and sepsis.  Lung toxicity is also of 
concern because of the use of bleomycin (Dearnaley, et al., 2001).  Testicular 
cancer most commonly afflicts men during their peak reproductive years.  
Therefore, infertility is an obvious area of concern in the treatment of TGCTs 
because chemotherapy frequently results in azoospermia.  This is reversible in 
70-80% of patients, and patients are usually counseled about the option of 
storing sperm (Dearnaley, et al., 2001).   However, the potential of treatment for 
testicular cancer resulting in infertility is still a major issue when considering 
quality of life for patients after treatment.   
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 Table 2.1.  TNM Staging System for Testicular Germ Cell Tumors 
Primary Tumor (T) Categories: 
 
T0 No evidence of cancer 
 
Tis Intratubular germ cell neoplasia (Carcinoma in situ); not invasive 
 
T1 Tumor spread to the membrane surrounding the testis 
 
T2 Tumor limited to testis with vascular/lymphatic invasion 
 
T3 Invasion of the spermatic cord with/without vascular/lymphatic invasion 
 
T4 Invasion of the scrotum with/without vascular/lymphatic invasion 
 
Regional Lymph Nodes (N) Categories: 
  
N0 No cancer cells present in lymph nodes 
 
N1 Metastases with  lymph node mass(es) ≤ 2cm 
 
N2 Metastases with lymph node mass(es) ˃ 2cm, but < 5cm 
 
N3 Metastases with lymph node mass(es) ˃ 5cm 
 
Metastasis (M) Categories: 
 
M0 No distant metastasis 
 
M1 Distant metastasis present 
 
M1a Metastasis to lungs or lymph nodes beyond the abdomen and pelvis 
 
M1b Metastasis to more distant organs, such as the lung and brain 
 
Serum (S) Marker Levels Categories: 
 
S0 Serum marker levels are normal 
 
S1 Serum markers are slightly elevated 
 
S2 Moderate increase in serum markers 
 
S3 Marker levels are very high 
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Testicular cancer metastasis  
Approximately 70 percent of testicular germ cell tumors metastasize, with 
the most frequent site of metastasis being the retroperitoneal lymph nodes 
(Jones, et al., 2006).  In non-seminomatous tumors, metastases are more likely 
to occur in the lungs, liver, and brain (Dearnaley, et al., 2001).  TGCTs are also 
less commonly found in the thymus and the pineal gland; it has been questioned 
whether TGCTs arising in these areas are due to metastases or if they are 
derived from PGCs that failed to complete their migration during embryonic 
development (Chaganti and Houldsworth, 2000).  Another hypothesis suggested 
for the presence of TGCTs located in the mediastinal region is the reverse 
migration of early stage TGCTs to these locations; this hypothesis is supported 
by data showing that many of the chromosomal aberrations seen in TGCTs of 
the gonad, including overrepresentation of chromosome 12p, were also present 
in TGCTs located in the mediastinal region (Chaganti, et al., 1994).   
  Very few studies have been published on genes involved in TGCT 
metastasis.  SDF1 (also known as CXCL12) and CXCR4 signaling partners 
appear to play a role in the pathology of TGCT metastasis (Gilbert, et al., 2009).  
CXCR4 and SDF1 belong to the CXC subgroup of a family of chemokines and 
their receptors (Vandercappellen, et al., 2008); this group is further divided based 
on the presence of an ELR (glutamic acid-leucine-arginine) motif; SDF1 lacks the 
ELR motif and binds to receptors, CXCR4 and CXCR7 (Vandercappellen, et al., 
2008).  Chemokines and their receptors function in regulating the migration of 
cells to a particular destination (Zlotnik, 2008).  SDF1 is angiogenic and has been 
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shown to be involved in cancer metastasis (Vandercappellen, et al., 2008; Zlotnik, 
2008). 
SDF1 and CXCR4 have been shown to be involved in PGC migration in 
the mouse and zebrafish (Doitsidou, et al., 2002; Molyneaux, et al., 2003).  PGCs 
express CXCR4, the receptor for the SDF1 ligand, and migrate towards regions 
where SDF1 is expressed, including the genital ridge, the final destination of the 
PGCs (Doitsidou, et al., 2002; Molyneaux, et al., 2003).  Gilbert, et. al. (2009) 
have presented data showing that SDF1 is expressed in adult human Sertoli cells, 
and CXCR4 is expressed in germ cells, with the exception of mature sperm.  
Furthermore, in vitro, SDF1 stimulated invasion and migration in a seminomatous 
TGCT cell line (Gilbert, et al., 2009).  These data provide evidence that 
CXCR4/SDF1 signaling may promote TGCT metastasis.   
 
TGFβ Superfamily 
The transforming growth factor-β (TGFβ) superfamily is a cytokine 
signaling family made up of more than 40 members in the human genome.  The 
most prominent members of this family include TGFβ, bone morphogenetic 
protein (BMPs), nodal, and activin (Massague and Gomis, 2006).  The 
superfamily members are found in a wide variety of cell types, and are involved 
in diverse biological processes, including, but not limited to, differentiation, 
migration, cellular division, and adhesion.  TGFβ and BMP have been implicated 
in cancer growth and metastasis (Massague and Gomis, 2006) as well as germ 
cell allocation and migration during development (Dudley, et al., 2007; Godin and 
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Wylie, 1991), making these two members of the superfamily of interest in 
testicular cancer research.  Furthermore, these two members of the TGFβ 
superfamily are negatively regulated by SKI (Akiyoshi, et al., 1999; Luo, et al., 
1999). 
 
SMADs 
TGFβ and BMP signal through cell surface receptors and downstream 
SMAD molecules (Figure 2.2).  TGFβ and BMP bind to transmembrane 
serine/threonine receptors, causing them to form a heteromeric complex 
composed of type I and type II receptors.  When these receptors are activated by 
BMP or TGFβ, they become phosphorylated, and in turn, they phosphorylate the 
downstream signaling molecules, the R-SMADs.  SMAD1, SMAD5, and SMAD8 
are phosphorylated by activated BMP receptors (Yamashita, et al., 1996), while 
SMAD2 and SMAD3 transmit TGFβ signals.  Upon activation, the R-SMAD forms 
a complex with the Co-SMAD, SMAD4; this complex translocates to the nucleus 
and activates transcription of BMP or TGFβ target genes (Luo, 2003).   
PGCs express high quantities of SMAD4, and SMAD1 is found in both 
PGCs and gonadal somatic cells (Pesce, et al., 2002).  SMAD1 may play a role 
in PGC specification.  SMAD1 knockout embryos die by 10.5 dpc, but, 
interestingly, these mice produce very few, if any, PGCs (Tremblay, et al., 2001).  
SMAD5 knockout is also embryonic lethal, and, these mice also display a great 
reduction in PGC number or none at all (Chang and Matzuk, 2001).  
Overexpression of SMAD4 in male transgenic mice causes a primary testicular 
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defect which results in Leydig cell hyperplasia and germ cell ablation, leading to 
infertility (Narula, et al., 2002).  In light of the fact that the occurrence of testicular 
germ cell tumors (TGCTs) is frequently associated with abnormalities of testicular 
development, including cryptorchidism, testicular atrophy, and infertility (Kanto, et 
al., 2004), this observation further implies that the BMP/SMAD signaling pathway 
is important in the development of germ cells and possibly testicular cancer. 
 
Transforming Growth Factor β 
As mentioned, TGFβ has been implicated in germ cell development and 
migration.  TGFβ inhibits murine PGC proliferation in vitro (Godin and Wylie, 
1991; Richards, et al., 1999) and also acts as a chemo-attractant for murine 
PGCs in vitro (Godin and Wylie, 1991).  TGFβ1 and 2 are produced by the Sertoli 
cells of the fetal and newborn rodent testis, while TGFβ2 and 3 are produced in 
Leydig cells, and TGFβ3 has been seen in gonocytes and spermatogonia 
(Loveland, et al., 2007).  TGFβ3 mRNA is the most abundantly expressed TGFβ 
isoform in the pre-pubertal and adult rat testis, and increased expression of 
TGFβ3 correlates with the onset of puberty and the induction of spermatogenesis 
(Mullaney and Skinner, 1993).   
For a cell to become malignant, it must acquire several characteristics that 
allow it to evade normal regulation.  The hallmark of cancer is uncontrolled 
proliferation, which involves autocrine growth stimulation, loss of contact 
inhibition, and protection from antiproliferative signaling.  In addition to this, the 
cell must acquire a mechanism for evading programmed cell death, or apoptosis.  
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Cancer cells also must become immortalized, meaning they are no longer limited 
to a certain number of cell divisions; they do not enter senescence.  In later 
stages of tumorigenesis, cancer cells form new vasculature to support the growth 
of the tumor, and, finally, the cancerous cells can gain the ability to invade the 
surrounding tissue and metastasize to distant sites.    
TGFβ plays diverging roles in the acquisition of these properties.  In the early 
stages of cancer, TGFβ may act as a tumor suppressor by inhibiting proliferation, 
while TGFβ signaling has been shown to promote invasion and metastasis in 
cancer progression, indicating that TGFβ signaling may also promote cancer 
progression (Leivonen and Kahari, 2007; Zhu, et al., 2007).  TGFβ is known to 
inhibit growth in many epithelial cell types, including keratinocytes, breast cancer 
cells, and colon cells (Jakowlew, 2006).  However in some cell types, high 
concentrations of TGFβ induce growth arrest, while low concentrations actually 
stimulate proliferation (Jakowlew, 2006).  Nevertheless, loss of response to 
TGFβ-induced growth inhibition is a mechanism by which many cancerous cells 
achieve increased proliferation.  Another tumor suppressing activity in which 
TGFβ is involved is apoptosis.  This action of TGFβ has not been as widely 
studied as the growth inhibitory actions, but TGFβ has been shown to induce 
apoptosis in various epithelial cells and has been implicated in controlling liver 
size through apoptosis (Jakowlew, 2006).  
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Figure 2.2.  TGFβ superfamily signaling cascade.  TGFβ and BMP bind to cell 
surface transmembrane serine/threonine receptors.  This binding induces the formation 
of heterodimers, consisting of type-I and type-II receptors.  The activated receptors 
induce phosphorylation of the R-SMADs, which, in turn, form a complex with the co-
SMAD, SMAD4.  This complex then translocates to the nucleus where it activates 
transcription of TGFβ or BMP-specific target genes.  This transcriptional activation is 
mediated by co-activators and co-repressors. 
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In contrast to the tumor suppressing activities that TGFβ displays in the 
early stages of tumorigenesis, TGFβ appears to promote tumor progression by 
stimulating invasion and metastasis.  Specifically, TGFβ is involved in epithelial 
to mesenchymal transition (EMT), which is a process by which cells become 
more migratory by losing some characteristics of epithelial cells and gaining 
some of the characteristics of mesenchymal cells.  Increasing TGFβ levels in cell 
lines causes increased tumor growth and metastasis in animal models (Jakowlew, 
2006).  In addition, TGFβ is more highly expressed in breast and colon 
metastases compared to the primary tumors.  This observation is also true for 
several other types of epithelial cancers (Jakowlew, 2006).  Tang et. al. (2003) 
reported evidence that TGFβ switches from a tumor suppressor to a 
prometastatic factor during breast cancer progression.  In their experiments they 
used four breast epithelial lines, all of which were derivatives of the “normal” 
immortalized MCF10A cell line, that spanned the progression from “normal” to 
highly malignant metastatic cancer cells.  Their data supports the hypothesis that 
TGFβ switches from acting as a tumor suppressor in the early stages of breast 
cancer when it is anti-proliferative, to promoting metastasis in later stages of 
breast cancer.  Their data suggest that the switch occurs at the transition from 
histologically low-grade to high-grade breast cancer (Tang, et al., 2003).   
 
Bone Morphogenetic Proteins 
Bone morphogenetic proteins (BMPs) are members of the TGFβ 
superfamily of growth factor signaling molecules.  At least 20 members of the 
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BMP subfamily have been identified, and they are expressed in a wide variety of 
tissues (Gazzerro and Canalis, 2006).  The BMP subfamily was originally named 
based on their role in bone formation; these proteins induced ectopic bone 
formation when implanted under the skin of rodents (Ducy and Karsenty, 2000).  
However, BMPs are now known to play various roles in embryonic development, 
organogenesis, differentiation, and cancer.  Several of the BMPs are expressed 
very early in embryogenesis, around the time of gastrulation, and are involved in 
organogenesis of various tissue types (Ducy and Karsenty, 2000).  While the 
expression pattern of BMPs is broad, they are often localized at areas of 
epithelial-mesenchymal interaction (Ducy and Karsenty, 2000).   
BMPs are also very important in germ cell development and 
spermatogenesis.  Mouse studies have shown that BMP4 and BMP8b are 
necessary for the allocation of PGCs during embryonic development (Lawson, et 
al., 1999; Ying, et al., 2000; Ying, et al., 2001).  Additional evidence has revealed 
that BMP signaling contributes to the maintenance of germ stem cells in the 
Drosophila testis (Kawase, et al., 2004).  BMP4 is also expressed in the early 
postnatal mouse testis but is downregulated prior to puberty (Pellegrini, et al., 
2003).  BMP signaling promotes proliferation of germ cells during 
spermatogenesis (Puglisi, et al., 2004).   
BMPs also appear to play conflicting roles in cancer progression.  BMPs 
have been shown to play a role in regulating stem cell differentiation (Varga and 
Wrana, 2005).  BMPs influence the differentiation of mesenchymal stem cells 
down the chondrogenic and osteogenic lineages, but BMPs have also been 
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shown to block neural differentiation (Ying, et al., 2003).  BMP2 and BMP4 
promote tumor growth through a variety of mechanisms, including angiogenesis, 
invasion, cell growth, and cell survival (Langenfeld, et al., 2005; Langenfeld, et al., 
2006; Montesano, 2007; Raida, et al., 2005; Rothhammer, et al., 2005).  About 
98% of lung carcinomas display increased BMP2 expression (Langenfeld, et al., 
2005).  Lung cancer cells with forced expression of BMP2 had increased 
expression of ID1 and displayed enhanced tumor growth in the lungs following 
intravenous injection into athymic nude mice (Langenfeld, et al., 2006).  This 
BMP-induced stimulation of tumor growth is associated with activation of 
SMAD1/5 (Langenfeld, et al., 2006).  BMP6 has been implicated in prostate 
cancer development and metastasis to bone (Darby, et al., 2008).  In PC3M 
prostate cancer cells, treatment with BMP6 did not affect proliferation; however, it 
did result in increased expression of matrix metalloproteinases, MMP-1 and 
MMP-9, and also caused increased migration and invasion (Darby, et al., 2008).  
However, BMP9 and BMP10 expression were found to be low or absent in 
prostate tumors, and forced expression of BMP9 or -10 in PC3 prostate cancer 
cells resulted in a decrease in growth, cell matrix adhesion, invasion, and 
migration (Ye, et al., 2009).  BMP9 and BMP10 also induced apoptosis in these 
cells via a SMAD-independent pathway (Ye, et al., 2008; Ye, et al., 2009).  This 
suggests that BMP6 has tumor promoting activities, while BMPs 9 and 10 may 
act as tumor suppressors in prostate cancer.  BMP2 promotes motility and 
invasion in MDA-231-D breast cancer cells and appears to be involved in 
metastasis to bone, but also did not affect their proliferation (Katsuno, et al., 
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2008).  BMP4 and BMP7 are increased in melanoma cells compared to normal 
melanocytes, and they appear to upregulate the expression of MMP-1, -2, -3, 
and -9, suggesting that BMPs may also promote metastasis in melanoma 
(Rothhammer, et al., 2008; Rothhammer, et al., 2005).  In colorectal cancer, 
expression of BMP7 is correlated with liver metastasis and poor prognosis 
(Motoyama, et al., 2008).  On the other hand, BMP3 expression was found to be 
down-regulated in 50 out of 56 primary colorectal tumors examined.  Bisulfite 
sequencing revealed hypermethylation of the BMP3 promoter in both human 
colorectal tumors and HT29 colorectal carcinoma cells.  Restoration of BMP3 
expression in colorectal cancer cell lines resulted in growth suppression (Loh, et 
al., 2008).   Upon review of this collection of data, it is evident that BMPs play 
diverse roles in cancer progression.  Again, the role of BMP in tumorigenesis 
may be dependent on the cell type and stage of cancer progression. 
 
Inhibitors of TGFβ and BMP Signaling 
The activity of TGFβ and BMP is regulated at multiple levels to maintain 
coordinated cellular functions, including regulation of ligand activity, extracellular 
antagonists, dominant negative pseudo-receptors, and blocking of downstream 
signaling by SMADs (Gazzerro and Canalis, 2006; Massague and Chen, 2000).  
TGFβ is secreted in a latent form and must be cleaved to be activated and 
recognized by cell surface receptors (Massague and Chen, 2000).  Several 
different molecules are involved in the activation of latent TGFβ.  This is a 
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complicated process that is not completely understood, but thrombospondin 1 
appears to be an important participator (Massague and Chen, 2000).   
Extracellular antagonists prevent signaling by binding to TGFβ or BMP 
and interfering with their interaction with cell surface receptors.  There are four 
groups of extracellular BMP antagonists:  noggin, the chordin family, twisted 
gastrulation, and the Dan family (Gazzerro and Canalis, 2006).  Noggin is 
secreted as a glycosylated protein and binds to BMP2, 4, 5, 6, and 7 with various 
degrees of affinity and prevents interaction with the BMP receptors.  Noggin does 
not interact with TGFβ (Gazzerro and Canalis, 2006).   Chordin is also a secreted 
glycoprotein and interacts specifically with BMP2, 4, and 7 (Gazzerro and 
Canalis, 2006).  Twisted gastrulation is another secreted glycoprotein that 
interacts with BMP2 and 4; it can act as both a BMP antagonist and a BMP 
agonist (Gazzerro and Canalis, 2006).  The Dan family is a family of 
glycoprotiens, consisting of at least nine members, that is capable of binding 
BMPs.  Most members of the Dan family are expressed during embryogenesis, 
but two members, gremlin and sclerostin, mediate BMP activity in the adult 
skeleton (Gazzerro and Canalis, 2006). 
BAMBI (BMP and activin membrane-bound inhibitor) is a pseudo-receptor 
with extracellular domains similar to TGFβ Type I receptors but lacks the 
intracellular kinase domain (Onichtchouk, et al., 1999).  BAMBI can inhibit 
signaling by forming heterodimers with TGFβ Type I receptors and inhibiting their 
activation (Massague and Chen, 2000).  BAMBI is capable of inhibiting both 
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TGFβ and BMP signals.  Transcription of BAMBI is upregulated by BMP, TGFβ, 
and Wnt (Gazzerro and Canalis, 2006). 
An additional way to regulate TGFβ superfamily signaling is by controlling 
the activity of the downstream signaling molecules, the SMADs.  There are 
several mechanisms that regulate SMAD signaling.  SMURF1 (SMAD 
ubiquitination regulator factor 1) is an E3 ubiquitin ligase that interacts with 
SMAD1 and 5 but not SMAD2 or 3 (Massague and Chen, 2000; Zhu, et al., 
1999).  Interaction with SMURF1 targets SMAD1 and 5 for ubiquitin-mediated 
degradation, inhibiting BMP signaling (Massague and Chen 2000).  BMP and 
TGFβ signaling is also mediated by a group of inhibitory SMADS (I-SMADs), 
SMAD6 and 7.  The I-SMADs bind to Type I receptors and inhibit the 
phosphorylation of R-SMADs.  SMAD6 more specifically inhibits BMP signaling, 
while SMAD7 inhibits both BMP and TGFβ signaling (Gazzerro and Canalis, 
2006).  Finally, co-repressors function to inhibit TGFβ superfamily signaling by 
binding to SMADs and preventing the transcription of target genes; these include 
TGIF, p300/CBP, and the SKI family (Gazzerro and Canalis, 2006; Massague 
and Wotton, 2000).  TGIF (transforming growth factor interacting factor) interacts 
with SMAD2 and 3, and prevents TGFβ induced gene transcription by recruiting 
histone deacetylases to SMAD-responsive DNA elements (Massague and 
Wotton, 2000).  In addition, LEFTY1 represses TGFβ and BMP signaling by 
inhibiting the receptor-induced phosphorylation of the R-SMADs (Ulloa and 
Tabibzadeh, 2001).  The SKI family, including SKI and SNO, are also potent 
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inhibitors of TGFβ and BMP signaling that function as transcriptional co-
repressors of SMAD proteins.   
 
SKI 
SKI was originally identified as a viral oncogene, v-ski, which is a 49 kDa 
polypeptide capable of inducing transformation in avian fibroblasts (Colmenares 
and Stavnezer, 1989; Stavnezer, et al., 1981).  Interestingly, v-ski is also capable 
of inducing myogenic differentiation in quail embryonic fibroblasts (Colmenares 
and Stavnezer, 1989).  c-Ski, the cellular homologue of v-ski, consists of eight 
coding exons, five of which are seen in v-ski (Stavnezer, et al., 1981).  SKI 
functions as a transcriptional regulator; the first exon of SKI contains motifs that 
are common to transcription factors, including a proline-rich region, a nuclear 
localization sequence, cysteine-histidine-rich metal-binding motifs, and paired 
amphipathic alpha-helices (Colmenares and Stavnezer, 1990).  This region of 
SKI is highly conserved in SNO (SKI-related novel), another member of the SKI 
family (Nomura, et al., 1989). 
SKI and SNO can function as negative regulators of the TGFβ superfamily, 
through interaction with SMADs, the downstream signaling molecules of the 
TGFβ superfamily (Akiyoshi, et al., 1999; Luo, et al., 1999).  There are several 
mechanisms by which the SKI family functions to repress TGFβ superfamily 
signaling.  SKI and SNO can repress TGFβ superfamily signaling by binding to 
SMAD complexes and recruiting other repressors, including the 
NCoR/Sin3/HDAC complex (Luo, et al., 1999; Massague and Chen, 2000).  
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Additionally, SKI and SNO can block the binding of the co-activator p300/CBP to 
the TGFβ-mediated R-SMADs (Akiyoshi, et al., 1999; Luo, et al., 1999).  SKI can 
also bind to MeCP2, a methyl-CpG-binding protein that functions in 
transcriptional repression (Kokura, et al., 2001).  Furthermore, interaction 
between SKI or SNO and SMAD4 can prevent the formation of functional 
complexes between SMAD4 and the R-SMADs (Luo, 2003).  SKI, but not SNO, 
has been shown to interact directly with the SMAD1/5-SMAD4 complexes to 
repress transcriptional activation of BMP target genes (Takeda, et al., 2004; 
Wang, et al., 2000).   
The role of SKI in cancer is complex and appears to be tissue and 
context-specific.  As previously mentioned, SKI was classified as a proto-
oncogene based on its ability to induce transformation in avian fibroblasts; yet 
SKI can also simultaneously induce muscle differentiation in quail embryo 
fibroblasts (Colmenares and Stavnezer, 1989; Stavnezer, et al., 1981).  In 
accordance with the transforming capability of SKI, some tumors, including 
melanoma, esophageal cancer, colon cancer, and pancreatic cancer, express 
high levels of SKI (Buess, et al., 2004; Fukuchi, et al., 2004; Heider, et al., 2007; 
Reed, et al., 2005).  SKI has also been considered pro-oncogenic because its 
upregulation in some cancers, such as melanoma and prostate, results in a loss 
of response to TGFβ-induced growth inhibition (Medrano, 2003; Xu, et al., 2000).  
SKI has been shown to be upregulated in pancreatic cancer, and siRNA-
knockdown of SKI in a PANC-1 pancreatic cancer cells restored TGFβ-induced 
growth inhibition (Heider, et al., 2007).   
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In contrast, loss of SKI function has been linked to tumorigenesis in mice 
heterozygous for a null mutation in the SKI gene (Shinagawa, et al., 2001), 
suggesting SKI may also act as a tumor suppressor. Mice lacking SKI display 
defects in neural and muscle development (Berk, et al., 1997; Colmenares, et al., 
2002), further indicating the importance of SKI in differentiation.  Recently, it has 
been reported that loss of SKI function promotes cancer progression by allowing 
TGFβ to promote metastasis in lung and breast cancer cells (Le Scolan, et al., 
2008).  In these studies, decreased SKI expression did not affect the proliferation 
of the lung and breast cancer cells (Le Scolan et al., 2008; Zhu et al., 2008).  
Thus, the role of SKI in cancer is not yet fully defined and appears to be 
dependent upon the cell type and possibly the stage of cancer. 
 
Hypothesis 
The rationale for the research presented in this text is that determining the 
role of SKI in testicular cancer will provide a better understanding of testicular 
cancer progression.  With a better understanding of the mechanisms behind 
testicular cancer progression, scientists will be able to design treatments that are 
aimed at the specific causes of testicular cancer, and these treatments may allow 
patients a better quality of life by potentially causing less severe side effects, 
such as preventing loss of fertility.  It is the hypothesis of this research that 
decreased SKI expression promotes testicular cancer progression by allowing 
unregulated TGFβ superfamily signaling, conferring an increased ability of 
testicular cancer cells to invade and metastasize. 
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CHAPTER III 
 
RESULTS 
 
SKI expression is decreased in TGCTs compared to normal 
testis  
Although SKI has been reported to have oncogenic activity in various 
cancers (Buess, et al., 2004; Reed, et al., 2005), SKI-deficient heterozygous 
mice have an increased susceptibility to tumorigenesis (Shinagawa, et al., 2001), 
indicating that SKI may have tumor suppressor activity.  RNA isolated from both 
normal human testis tissue and human tumor samples, including seminoma, yolk 
sac, and mixed germ cell tumors was analyzed for SKI, SNO, and CCND2 mRNA 
expression using quantitative real time PCR.  SKI mRNA expression was 
decreased in all types of testicular tumors compared to normal testis samples 
(Figure 3.1 A).  The expression of SNO (Figure 3.1 B), another member of the 
SKI family, was not significantly different in tumor and normal testis samples.  
CCND2 was used as a positive control, as its expression is known to increase in 
several types of cancer, and has specifically been shown to be increased in 
testicular cancer (Bartkova, et al., 1999).  As expected, CCND2 expression was 
elevated in testicular tumors compared to normal tissue (Figure 3.1 C).  
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Figure 3.1. Decreased SKI expression in human testicular germ cell tumors.  Real 
time PCR analysis comparing mRNA levels in human testicular germ cell tumors, 
including seminoma (n = 16), yolk sac tumors (n = 11), and mixed tumors (n = 7), to 
normal testicular tissue samples (n = 20).  (A)  SKI mRNA expression in germ cell 
tumors compared to normal testis. (B)  SNO, a member of the SKI family, was also 
measured.  (C)  CCND2 is used as a control.  mRNA levels were normalized to 18S 
RNA.  Data were analyzed using 2-∆∆Ct method, and error bars indicate the 95% 
confidence interval. 
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SKI expression varies among different human cell types 
 SKI expression has previously been shown to vary among different 
cancerous cell types (Buess, et al., 2004; Fukuchi, et al., 2004; Heider, et al., 
2007; Reed, et al., 2005; Zhu, et al., 2007), suggesting that SKI may play 
diverging roles in the development and progression of cancer dependent on cell 
type and environment.  In order to determine the role that SKI plays in testicular 
cancer, a human embryonal carcinoma cell line, NCCIT, was used.  To 
determine the relative level of SKI protein expression in NCCIT testicular cancer 
cells, we compared SKI expression in NCCIT cells to various other human 
cancerous and normal cells (Figure 3.2).  These cell lines included human 
hepatocelluar carcinoma (HEPG2), human normal mammary cells (HMEC), 
human breast cancer cells (MCF7 and T47D), human lung adenocarcinoma 
(A549), human melanoma cells (SbCl2, WM1366, and WM9), human colorectal 
carcinoma (HCT116), human neuroblastoma (SK-N-AS and SK-N-SH), and 
human embryonal carcinoma (NT2/D1 and NCCIT).  
  In accordance with previously published data, we found that SKI is 
expressed at varying levels in different cancerous and normal human cell types.  
It has previously been reported that SKI expression increases with cancer 
progression in human melanoma (Reed, et al., 2001).  In support of this, we 
found that SKI expression is higher in WM1366 human melanoma cells, which 
are categorized in the vertical growth phase, compared to expression in SbCl2 
human melanoma cells, which are primary melanoma cells in the radial growth 
phase.  SKI expression is higher still in WM9 human melanoma cells, which are 
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categorized as metastatic melanoma (Figure 3.2).  SKI expression was relatively 
low in A549 human lung carcinoma cells (Figure 3.2), which was also previously 
observed (Zhu, et al., 2007).  Increased expression of SKI has previously been 
reported in human colorectal carcinoma (Buess, et al., 2004), and, in accordance 
with this, SKI expression was found to be high in HCT116 human colorectal 
carcinoma cells (Figure 3.2).  SKI was expressed at similar levels in HMEC 
human normal mammary cells and MCF7 human mammary adenocarcinoma, 
derived from a pleural effusion, but SKI expression was lower in T47D human 
ductal carcinoma, also derived from a pleural effusion.  In comparison to these 
cell lines, SKI was expressed at an intermediate level in NCCIT and NT2/D1 
human embryonal carcinoma cells (Figure 3.2), both of which were derived from 
mediastinal metastases.   
 
Manipulation of SKI expression in NCCIT cells 
Our data shows that SKI expression is reduced in human testicular germ cell 
tumors, therefore, we wanted to compare the effects of decreased SKI and 
forced SKI expression using an in vitro model of testicular cancer.  For these 
experiments we used the human testicular cancer cell line, NCCIT, which is 
classified as embryonal carcinoma (or non-seminoma).  Since some SKI 
expression was detected in NCCIT cells via western blotting, siRNA was used to 
knockdown the levels of SKI to determine the effects of decreased SKI.  Three 
siRNAs against different regions of the SKI gene (designated siSKI-1, siSKI-2, 
and siSKI-3) were used individually to knockdown SKI levels.  A non-specific 
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Figure 3.2.  SKI Expression in Human Cell Lines.  SKI protein levels were analyzed 
by western blotting (upper panel) in various human normal and cancerous cell lines.  α-
tubulin was used as a loading control. Protein levels were quantified by densitometry 
(lower panel) and expressed relative to α-tubulin.  Data represents three combined trials; 
error bars indicate SEM.  
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siRNA was used as a control, and cells treated with the transfection reagent 
alone (mock transfection) were used to ensure that there were no adverse 
consequences from the transfection procedure.  Cells were treated with siRNA 
over a 72 hr time period.  To assess SKI knockdown, SKI mRNA and protein 
levels were measured using real-time PCR and western blotting at 24, 48, and 72 
hrs.  In NCCIT cells, siRNAs siSKI-2 and siSKI-3 were able to knockdown SKI 
mRNA and protein levels by 45-60% 48 h after transfection, while siSKI-1 siRNA 
was less effective in knocking down SKI expression in NCCIT cells (Figure 3.3 A 
and B).  
To assess the effects of forced SKI expression on NCCIT cells, the cells 
were transfected with a SKI expression vector, and the empty vector was used 
as a control.  SKI protein levels were assessed at 24, 48, and 72 hrs.  In NCCIT 
cells transfected with the SKI expression vector, SKI protein levels were 
increased by 43% at 48 hrs (Figure 3.3 C).  
 
Effects of SKI on migration in NCCIT cells 
NCCIT cells were plated on Matrigel-coated plates and were treated with 
one of the three SKI siRNAs or the non-specific control siRNA.  A scrape was 
made in the cell monolayer 48 hrs after siRNA transfection, and the cells were 
analyzed for percent closure of the scrape after a 20 hr incubation period.  
NCCIT cells treated with siSKI-2 and siSKI-3 siRNA accomplished a 39.1% (p < 
0.05) and 40.6% (p < 0.05) increase, respectively, in percent closure of the 
scraped area compared to NCCIT cells treated with the non-specific control  
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Figure 3.3.  siRNA Knockdown and Forced Expression of SKI in NCCIT Cells.  SKI 
mRNA and protein levels were measured at 48 hrs after transfection with one of three 
SKI siRNAs, a control siRNA, a SKI expression vector, or the control vector.  (A) siRNA 
knockdown of SKI confirmed by real time PCR.  Data were analyzed using 2-∆∆Ct method; 
data represents three individual trials; error bars indicate the 95% confidence intervals.  
(B) siRNA knockdown of SKI in NCCIT cells confirmed by western blotting; α-tubulin was 
used as a loading control.  Protein levels were quantified by densitometry and are 
expressed relative to α-tubulin.  Data represents three combined trials; error bars 
indicate SEM; * indicates a significant difference with p < 0.05 as assessed by One-way 
ANOVA with Bonferroni adjustment.  Mock – mock transfection; Control – non-specific 
siRNA; siSKI-1, siSKI-2, and siSKI-3 represent individual siRNAs.  (C)  Forced SKI 
expression in NCCIT cells confirmed by western blotting; α-tubulin was used as a 
loading control.  Protein levels were quantified by densitometry and are expressed 
relative to α-tubulin.  Data represents three combined trials; error bars indicate SEM; * 
indicates a significant difference with p < 0.05, as assessed by T-test.   
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siRNA (Figure 3.4, panel A), while NCCIT cells treated with siSKI-1 siRNA 
achieved a 19.7% increase (p < 0.05) in percent closure of the scraped area 
compared to the control siRNA.  The greater increase in migration seen in cells  
treated with siSKI-2 and siSKI-3 compared to that seen with siSKI-1 correlates 
with the data showing that siSKI-2 and siSKI-3 were more efficient than siSKI-1 
in knocking down the level of SKI mRNA and protein. 
If decreased SKI levels play an important role in promoting the metastasis 
of testicular cancer cells, one would expect that forcing the expression of SKI in 
these cells would have the opposite effect, inhibiting the migration of these cells.  
To test this hypothesis, we forced expression of SKI in NCCIT cells by 
transfecting them with a vector containing the SKI gene and performed cell 
scrape assays.  Cells transfected with the empty vector were used as a control.  
We found that forcing expression of SKI in NCCIT cells does, indeed, 
significantly decrease the percent closure of the scraped area by approximately 
20% relative to the control-transfected cells (Figure 3.4, panel B).  Therefore, the 
level of SKI expression does appear to directly affect the ability of NCCIT cells to 
migrate. 
 
Effects of SKI on invasion in NCCIT cells 
To confirm the observations seen in the cell scrape assays, Matrigel 
invasion chambers were used to further assess the invasive potential of NCCIT 
cells in response to the level of SKI expression.  NCCIT cells treated with siSKI-2 
and siSKI-3 siRNA displayed a 75% and 71% increase (p < 0.05), respectively, in  
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the number of invading cells compared to NCCIT cells treated with the control 
siRNA (Figure 3.5A).  NCCIT cells treated with the siSKI-1 siRNA did not display 
a significant change in the number of invading cells, which, again, correlates with  
the level of knockdown seen in the cells treated with siSKI-1 siRNA.  Similar to 
data collected in the cell scrape assays, forcing the expression of SKI in NCCIT 
cells resulted in a 44% decrease in the number of invading cells compared to the 
cells treated with the control vector (Figure 3.5B). 
 
SKI expression does not affect the growth rate of NCCIT cells 
SKI expression has previously been reported to affect growth in some 
cancers, including pancreatic cancer (Heider, et al., 2007).  In order to determine 
if SKI expression affects cellular proliferation in NCCIT cells, the growth rate of 
NCCIT cells treated with SKI siRNA was determined via trypan blue dye 
exclusion cell counts 24, 48, and 72 hours after transfection with siRNA, the SKI 
expression vector, or the control vector (Figure 3.6A, B).  There was no 
significant change in the rate of growth in either the NCCIT cells treated with SKI 
siRNA compared to cells treated with the control siRNA or NCCIT cells treated 
with the SKI expression vector compared to cells treated with the control vector 
(Figure 3.6A, B).  In addition, cell counts were performed after each cell scrape 
assay (data not shown), and these cell counts also revealed no difference in 
growth among cells with different levels of SKI expression.  These data indicate 
that SKI expression does not affect proliferation in NCCIT cells.   
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Figure 3.5.  Matrigel Invasion Assay on NCCIT cells.  (A) Number of siRNA-treated 
NCCIT cells migrating through the Matrigel invasion chamber, error bars represent SEM, 
*indicates a significant difference compared to Control siRNA with p < 0.05.  (B) Number 
of NCCIT cells treated with either the SKI expression vector or the control vector 
migrating through the Matrigel invasion chamber, error bars represent SEM, *indicates a 
significant difference compared to Control vector with p < 0.05 as assessed by One-way 
ANOVA with Bonferroni adjustment.   
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Figure 3.6. Cell Growth Measured by Trypan Blue Cell Counts.  Cells were collected 
at 48hrs after transfection and were counted using trypan blue dye exclusion.  Data are 
reported as the log of the total cell number; error bars represent SEM.  (A)  NCCIT cells 
receiving mock transfection (Mock), treatment with the non-specific control siRNA 
(Control), or treatment with one of the three SKI siRNAs (siSKI-1, siSKI-2, or siSKI-3).  
(B)  NCCIT cells transfected with the SKI expression vector (+SKI) or the control vector 
(Control).  There were no significant differences among the treatment groups as 
assessed by One-way ANOVA with Bonferroni adjustment.   
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  Effect of TGFβ on cell migration in SKI-knockdown cells 
 SKI is a negative regulator of the TGFβ superfamily signaling molecules, 
including TGFβ and BMP.  We have shown that SKI expression is decreased in 
human testicular cancer samples compared to normal human testis samples.  
We have also shown that transiently reducing the levels of SKI in NCCIT human 
testicular cancer cells enhances their ability to migrate and invade in vitro.  
Therefore, we sought to determine if decreased SKI expression in NCCIT 
testicular cancer cells affects migration by allowing increased signaling from 
TGFβ superfamily signaling molecules.   
To determine this, we performed stable transfections with a SKI shRNA 
vector to generate stable SKI-knockdown NCCIT cells (Figure 3.7).  These cells 
were exposed to TGFβ and/or TGFβ blocking antibody, and their ability to 
migrate was assessed via cell scrape assays.  As we previously observed with 
transient SKI knockdown, cells with decreased SKI expression had significantly 
increased migration compared to cells treated with the control shRNA vector 
(Figure 3.8).  If reduced SKI expression enhanced migration by allowing 
increased TGFβ signaling, one would expect that adding TGFβ would further 
enhance the migration of shSKI NCCIT cells, but adding TGFβ to shNC NCCIT 
cells would not necessarily have an effect.  However, treating either shSKI or 
shNC NCCIT cells with TGFβ does not appear to affect their migration, nor does 
treating shSKI or shNC NCCIT cells with TGFβ blocking antibody have an effect 
on their migration (Figure 3.8).   
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Figure 3.7.  SKI knockdown in shSKI NCCIT cells.  Representative western blot 
showing the expression of SKI in shNC NCCIT cells and shSKI NCCIT cells.  α-tubulin 
was used as a loading control.  Numbers indicate the level of SKI expression relative to 
the level in shNC NCCIT cells. 
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Figure 3.8.  Effect of TGFβ on the migration of shNC and shSKI NCCIT cells.  Bar 
graph representing the % closure in cell scrape migration assays using shNC NCCIT 
cells (black bars) and shSKI NCCIT cells (white bars) ± 0.1nM TGFβ ± 200nM TGFβ 
blocking antibody. Data represents three trials; error bars indicate SEM; Groups labeled 
A and B are significantly different from each other with p < 0.05 as assessed by One-
way ANOVA with Bonferroni adjustment. 
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Since addition of TGFβ to SKI-knockdown NCCITs does not appear to 
affect the migration of these cells, one would question whether the TGFβ 
pathway is active in these cells.  To explore this question, we tested TGFβ-
induced phosphorylation of SMAD2 in shNC and shSKI NCCIT cells.  SMAD2 
was readily detected by western blotting and was expressed at a constant level 
regardless of the addition of TGFβ.  However, p-SMAD2 was only faintly 
detected by western blotting, and addition of 0.1nM TGFβ for 2 hours to either 
shNC or shSKI NCCIT cells resulted in a slight induction of SMAD2 
phosphorylation (1.6 fold in shNC NCCIT cells and 1.8 fold in shSKI NCCIT cells) 
(Figure 3.9).   
 
Effect of BMP on cell migration in SKI-knockdown cells 
 SKI is known to repress both TGFβ and BMP signaling by interacting with 
SMAD proteins  (Akiyoshi, et al., 1999; Luo, et al., 1999).  SKI can interact with 
both TGFβ-specific SMADs, SMADs 2 and 3, and BMP-specific SMADs, SMADs 
1, 5, and 8, as well as the co-SMAD, SMAD4.  Hence, we treated shSKI and 
shNC NCCIT cells with BMP and/or noggin, a BMP inhibitor, to determine if 
increased BMP signaling affects migration in SKI-deficient testicular cancer cells.  
This was also assessed via cell scrape migration assays.  ShSKI NCCIT cells 
treated with BMP had a significant increase in percent closure of the cell scrape 
compared to both untreated shSKI cells and shNC cells, untreated or treated with 
BMP (Figure 3.10).  Treating shNC NCCIT cells with BMP did not affect their 
migration (Figure 3.10).  In addition, treating shSKI cells with noggin, a BMP  
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Figure 3.9.  Induction of SMAD2 phosphorylation by TGFβ in shNCCIT cells.  Upper 
panel is a representative western blot showing the expression of phospho-SMAD2 in 
shNCCIT cells ± TGFβ treatment (0.1nM) for 2 hrs.  α-tubulin was used as a loading 
control.  Numbers indicate the level of p-SMAD2 relative to the level in shNC NCCIT 
cells – TGFβ.  Lower panel is a representative western blot showing the expression of 
SMAD2 in shNCCCIT cells ± TGFβ treatment.  α-tubulin was used as a loading control.   
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inhibitor, reduced their level of migration back to the level of untreated shNC 
NCCIT cells (Figure 3.10).  Treating shNC NCCIT cells with noggin also slightly 
reduced their migration.  This indicates that in NCCIT cells, reduced SKI 
expression enhances BMP signaling, which promotes migration.    
To demonstrate the activity of the BMP pathway in NCCIT cells, shNC or 
shSKI NCCIT cells were treated with BMP, noggin, or both and assessed for 
phosphorylation of SMAD1/5/8.  Treating shNC or shSKI NCCIT cells with BMP 
induced the phosphorylation of SMAD1/5/8 (Figure 3.11).  This effect was 
inhibited in the presence of noggin.  As expected, SMAD1/5/8 phosphorylation 
was induced by BMP regardless of SKI expression.  P-SMAD1/5/8 expression 
was approximately 2.3 and 2.5 fold higher in shNC NCCIT and shSKI NCCIT 
cells, respectively, treated with BMP compared to untreated cells.  Treatment 
with BMP, noggin, or both did not affect the level of SMAD5 expression (Figure 
3.11 lower panel).  As expected, the presence of SKI did not affect SMAD 
phosphorylation because SKI does not act at the level of inhibiting SMAD 
phosphorylation, but, rather, prevents SMAD-induced gene transcription. 
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Figure 3.10.  Effect of BMP on migration of shNC and shSKI NCCIT cells.  Bar 
graph representing the percent closure in cell scrape migration assays using shNC 
NCCIT cells (black bars) and shSKI NCCIT cells (white bars) ± 10ng/mL BMP, ± 
0.1µg/mL noggin.  Data represents the mean of three trials; error bars indicate SEM; 
Groups labeled A, B, C and D are each significantly different from each other with p < 
0.05 as assessed by One-way ANOVA with Bonferroni adjustment. 
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Figure 3.11.  Phosphorylation of SMAD1/5/8 by BMP4.  The upper panel is a 
representative western blot showing the expression of phospho-SMAD1/5/8 in shNCCIT 
cells ± 10ng/mL BMP, ± 0.1µg/mL noggin treatment for 2 hrs.  Numbers indicate the 
level of p-SMAD1/5/8 relative to p-SMAD1/5/8 levels in shNC NCCIT cells + BMP.  The 
lower panel shows SMAD5 expression in shNCCIT cells ± 10ng/mL BMP, ± 0.1µg/mL 
noggin treatment for 2 hrs.  α-tubulin was used as a loading control for both western 
blots..   
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SKI Expression in shNC and shSKI NCCIT cells treated with BMP 
and/or Noggin 
 
 Real time PCR analysis was used to test the level of SKI knockdown in 
shSKI NCCIT cells compared to shNC NCCIT cells and to determine if addition of 
BMP or noggin affects the level of SKI.  SKI mRNA expression was significantly 
reduced by about 80% in shSKI NCCIT cells compared to shNC NCCIT cells 
(Figure 3.12).  Addition of BMP and/or noggin did not significantly alter the level 
of SKI mRNA in these cells.   
 
Microarray Analysis 
 We found that experimentally reducing SKI expression in NCCIT cells 
resulted in an enhanced invasive phenotype.  Therefore we next sought to 
determine if reducing SKI expression in these NCCIT cells allowed an 
upregulation of genes involved in promoting metastasis and downregulation of 
genes that function to inhibit cellular invasion.  Furthermore, since SKI is a 
transcription factor and a co-repressor of the TGFβ superfamily, we were 
interested in identifying changes in the expression patterns of genes involved in 
TGFβ superfamily signaling, especially genes involved in BMP signaling because 
we have shown that BMP enhances the invasive phenotype seen in shSKI 
NCCIT cells.  In order to identify potential downstream targets of SKI that may 
play a role in metastasis, microarray analysis was performed to compare the 
gene expression profile of shSKI NCCIT cells to that of the shNC NCCIT cells.  
Statistical analysis of microarray (SAM) and gene set enrichment analysis (GSEA) 
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Figure 3.12.  SKI mRNA expression in shNCCIT cells treated with BMP and/or 
noggin.  Real time PCR analysis comparing SKI mRNA expression in shNC NCCIT 
cells ± 10ng/mL BMP, ± 0.1µg/mL noggin compared to shSKI NCCIT cells ± 10ng/mL 
BMP, ± 0.1µg/mL noggin.  RNA levels were normalized to 18S RNA.  Data represents 
three individual trials and was analyzed using 2-∆∆Ct method; error bars indicate the 95% 
confidence interval. 
 
 58
 (http://www.broadinstitute.org/gsea) were used to identify significant genes and 
gene families that were differentially expressed in shSKI NCCIT cells compared 
to shNC NCCIT cells.   
Statistical analysis of microarrays (SAM) revealed 963 human gene 
probes were differentially expressed in shSKI and shNC NCCIT cells.  Of these 
differentially expressed genes, 593 probes were upregulated by at least 1.5 fold 
in shSKI NCCIT cells, and 370 probes were downregulated by at least 1.5 fold in 
shSKI NCCIT cells compared to shNC NCCIT cells.  The differentially expressed 
genes belong to diverse signaling pathways and are involved in a variety of 
cellular processes.   
Gene Set Enrichment Analysis (GSEA) was used to identify gene sets 
involved in specific biological processes that were significantly upregulated in 
shSKI NCCIT cells compared to shNC NCCIT cells.  GSEA uses four key 
statistics for determining gene set enrichment.  These include the enrichment 
score (ES), the normalized enrichment score (NES), the false discovery rate 
(FDR), and the nominal p-value.  The ES value ranks the gene sets according to 
the degree to which they are over-represented at the top or bottom of a ranked 
list of genes.  A positive ES indicates a correlation with the shSKI phenotype, 
while a negative ES indicates a correlation with the control phenotype.  If several 
genes from a gene set are clustered at the top of the ranked list, the ES value 
would be higher, and that gene set would be more strongly correlated with the 
shSKI phenotype.  The NES can be used to compare analysis results across 
gene sets because it accounts for differences in gene set size and in correlations 
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between gene sets and the expression dataset.  The FDR is the estimated 
probability that a gene set with a given NES represents a false positive finding.  
The nominal p value provides an evaluation of the statistical significance of the 
enrichment score for a single gene set (http://www.broadinstitute.org/gsea).  The 
FDR is adjusted for gene set size and multiple hypothesis testing, but the 
nominal p value is not.  The family-wise error rate (FWER) is a more stringent 
measure of significance that corrects for multiple hypothesis testing.  This more 
conservative cutoff resulted in only a few statistically significant results with 
FWER less than 0.05.  In our analysis we were primarily interested in identifying 
potential targets of SKI that may play a role in metastasis, therefore we 
considered gene sets with both an FDR less than 0.25 and a nominal p value 
less than 0.05.   
Within the gene sets, GSEA provides the rank in gene list, the rank metric 
score, and the running ES.  GSEA assigns each gene a rank metric score, which 
is computed using a “Signal2Noise” measurement that uses the difference of 
means scaled by the standard deviation.  This provides a measurement of the 
gene’s correlation with the phenotype being studied and is used to position the 
gene in the ranked list.  The rank values go from positive to negative as you 
move down the list, with a higher positive value indicating a stronger correlation 
with the shSKI phenotype and a negative value indicating a correlation with the 
control phenotype.  The rank in gene list indicates the position of the gene in a 
ranked list of genes.  Thus a lower value indicates a higher position on the 
ranked list and a stronger correlation with the shSKI phenotype.  The running ES 
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is the enrichment score at this point in the ranked list of genes.  During the 
analysis, GSEA creates a running sum statistic by walking down the ranked list of 
genes, and this value is increased when the gene belongs to the gene set being 
tested.  The magnitude of the ES from zero is indicative of the correlation of that 
gene with the phenotype, with an ES closer to one being a strong correlation.    
GSEA identified 101 gene sets that were enriched in shSKI NCCIT cells 
compared to shNC NCCIT cells with a nominal p-value (p-nominal) less than 
0.05 and a false discovery rate (FDR) less than 0.25 (Table 3.1).  Of these 101 
gene sets, the gene set “Regulation of MAP Kinase Activity” contained 20 genes 
that were enriched in shSKI NCCIT cells compared to shNC NCCIT cells with a 
family-wise error rate p-value (FWER) of less than 0.05, indicating a higher level 
of significance (Table 3.2).  Some interaction between the MAPK and BMP 
pathways has previously been shown to be involved in cell fate determination.  
FGF8 and IGF2, both of which activate MAPK signaling, have been shown to 
inhibit nuclear localization of SMAD1 (Massague, et al., 2005).  However, these 
specific genes were not identified through GSEA as being enriched in the SKI-
knockdown cells.  It is possible that upregulation of MAPK signaling may be a 
compensation mechanism to the increased activity of the BMP pathway in SKI-
knockdown cells.  Activation of the Ras/MAPK pathway has also been shown to 
inhibit SMAD2 nuclear localization, preventing TGFβ signaling (Massague, 2003).  
It is possible that alterations in MAPK signaling may contribute to the lack of 
response seen with the addition of TGFβ to the shSKI NCCIT cells.  A specific 
link between SKI and the MAPK pathway has not been shown, thus our data 
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suggest that there may be further interaction between MAPK signaling and TGFβ 
superfamily signaling.   
Also of interest to this research is the gene set “Transforming Growth 
Factor Beta Receptor Signaling Pathway,” which met the dual criteria of nominal 
p-value less than 0.05 and FDR less than 0.25 (Table 3.3).  This signaling 
pathway is of interest because SKI is known to be a co-repressor of the TGFβ 
superfamily.  Both SMAD7 and LEFTY1, which are known to inhibit TGFβ 
signaling, were enriched in SKI knockdown cells.  This was also seen in the SAM 
analysis (Table 3.6).  Upregulation of these genes may contribute to the lack of 
response seen with the addition of TGFβ to shSKI NCCIT cells. 
In review of the SAM data set, other signaling families of interest were 
identified, including the WNT signaling family, genes belonging to the family of 
chemokines and their receptors, and additional TGFβ superfamily signaling 
genes.  Several genes from the WNT signaling family (Table 3.4) were 
differentially expressed in shSKI and shNC NCCIT cells.  The importance of the 
WNT signaling pathway in colorectal cancer has been widely reported, and the 
WNT pathway has also been implicated in epithelial to mesenchymal transition 
(reviewed in (Huang and Du, 2008), which suggests that this signaling family 
may play a role in the enhanced invasive phenotype seen in the shSKI NCCIT 
cells.   
Additionally, several chemokines and chemokine receptors were 
differentially expressed in shSKI and shNC NCCIT cells (Table 3.5).  
Chemokines and their receptors are known to play an important role in 
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tumorigenesis, especially in tissue directed metastasis (Vandercappellen, et al., 
2008).  Based on our observed phenotype in SKI-knockdown cells, CXCR4 is of 
particular interest in this group of chemokines because CXCR4 has previously 
been implicated in testicular cancer metastasis.  CXCR4 was upregulated in 
shSKI NCCIT cells compared to shNC NCCIT cells.  This finding supports our 
hypothesis that decreased SKI expression promotes metastasis in testicular 
cancer, and it also suggests that SKI may regulate the expression of CXCR4 in 
testicular cancer cells.   
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Table 3.1.  Gene Sets Enriched in shSKI NCCIT Cells Identified by GSEA. 
NAME OF GENE SET # of 
GENES 
ES NES p-nominal FDR FWER RANK AT 
MAX 
Transcription Initiation 35 0.5738 2.1093 0.0000 0.0138 0.0110 1717
Protein DNA Complex Assembly 48 0.5146 1.9813 0.0000 0.0308 0.0530 833
Positive Regulation of MAP Kinase Activity 46 0.5157 1.9244 0.0000 0.0367 0.0990 4160
Transcription Initiation from RNA Polymerase II 
Promoter 
29 0.5998 1.9896 0.0000 0.0376 0.0440 1717
Activation of MAPK Activity 40 0.5216 1.9299 0.0000 0.0396 0.0890 2645
Regulation of Mitotic Cell Cycle 22 0.5415 1.8599 0.0000 0.0415 0.1650 4833
Cell Structure Disassembly during Apoptosis 18 0.5250 1.9436 0.0000 0.0421 0.0810 1920
Apoptotic Nuclear Changes 19 0.4939 1.8827 0.0000 0.0427 0.1440 1920
Amino Acid Transport 26 0.5672 1.8621 0.0000 0.0450 0.1610 971
Negative Regulation of MAP Kinase Activity 17 0.6590 1.8910 0.0000 0.0452 0.1380 3196
Amine Transport 38 0.5268 1.8231 0.0000 0.0464 0.2480 971
Transforming Growth Factor Beta Receptor 
Signaling Pathway 
36 0.5141 1.8143 0.0000 0.0477 0.2640 2714
Glycoprotein Metabolic Process 90 0.4294 1.8248 0.0000 0.0487 0.2430 1069
Regulation of MAP kinase Activity 66 0.5468 2.0014 0.0000 0.0500 0.0370 3718
Negative Regulation of Transferase Activity 35 0.5344 1.8266 0.0000 0.0510 0.2330 3581
Glycoprotein Biosynthetic Process 74 0.4304 1.8295 0.0000 0.0521 0.2260 1069
Regulation of Organelle Organization and 
Biogenesis 
40 0.4514 1.7190 0.0000 0.0696 0.4680 3877
Central Nervous System Development 121 0.3945 1.7582 0.0000 0.0696 0.3680 4987
DNA Catabolic Process 23 0.4721 1.7627 0.0000 0.0702 0.3610 1802
Transmembrane Receptor Protein Serine 
Threonine Kinase Signaling Pathway 
47 0.4056 1.7196 0.0000 0.0718 0.4670 2714
Response to Oxidative Stress 45 0.4269 1.7649 0.0000 0.0718 0.3500 1842
Regulation of Cytoskeleton Organization and 
Biogenesis 
30 0.4925 1.7260 0.0000 0.0758 0.4500 3877
Regulation of Hydrolase Activity 75 0.4409 1.7318 0.0000 0.0774 0.4360 4997
NAME OF GENE SET # of 
GENES 
ES NES p-nominal FDR FWER RANK AT 
MAX 
Positive Regulation of Catalytic Activity 158 0.4067 1.7270 0.0000 0.0783 0.4480 4433
Negative Regulation of Catalytic Activity 68 0.3798 1.6866 0.0000 0.0815 0.5600 3581
Positive Regulation of Transferase Activity 85 0.4080 1.6769 0.0000 0.0821 0.5790 2645
Protein Kinase Cascade 286 0.3542 1.6784 0.0000 0.0829 0.5780 3866
Activation of Immune Response 16 0.6843 1.6813 0.0000 0.0832 0.5700 3006
Apoptotic Program 59 0.4217 1.6514 0.0000 0.0866 0.6340 4433
Regulation of Catalytic Activity 268 0.3336 1.6316 0.0000 0.0909 0.6780 4917
Organic Acid Transport 42 0.4124 1.6202 0.0000 0.0926 0.7050 971
Regulation of Transferase Activity 159 0.3424 1.6027 0.0000 0.1006 0.7430 3718
Carboxylic Acid Transport 41 0.4180 1.5956 0.0000 0.1050 0.7580 971
Enzyme Linked Receptor Protein Signaling 
Pathway 
139 0.3190 1.5842 0.0000 0.1131 0.7750 4401
Protein Secretion 31 0.3958 1.5519 0.0000 0.1283 0.8370 3322
Homeostasis of Number of Cells 20 0.5226 1.7366 0.0020 0.0778 0.4240 3790
Cell Substrate Adhesion 37 0.4951 1.6765 0.0040 0.0780 0.5790 3216
Cell Matrix Adhesion 36 0.4787 1.6333 0.0040 0.0911 0.6730 3216
Response to Abiotic Stimulus 87 0.4134 1.6947 0.0040 0.0776 0.5220 5363
Regulation of Signal Transduction 219 0.3099 1.4788 0.0041 0.1600 0.9360 3826
Regulation of Kinase Activity 155 0.3331 1.5612 0.0041 0.1250 0.8200 3718
MAPKKK Cascade GO 0000165 103 0.4030 1.6765 0.0041 0.0801 0.5790 2645
Mesoderm Development 21 0.5195 1.5343 0.0042 0.1349 0.8740 6231
Chromosome Segregation 32 0.5086 1.7238 0.0059 0.0739 0.4550 472
Glycolipid Metabolic Process 16 0.5776 1.8312 0.0059 0.0551 0.2230 601
Organelle Organization and Biogenesis 469 0.2734 1.5045 0.0061 0.1484 0.9070 2644
Secretion 174 0.3212 1.4673 0.0062 0.1583 0.9450 3334
Regulation of Protein Kinase Activity 153 0.3286 1.5380 0.0062 0.1335 0.8650 3718
Oxygen and Reactive Oxygen Species Metabolic 
Process 
20 0.6436 1.7050 0.0063 0.0760 0.5030 4224
Positive Regulation of Transcription from RNA 
Polymerase II Promoter 
65 0.3795 1.5523 0.0078 0.1299 0.8370 3508
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NAME OF GENE SET # of 
GENES 
ES NES p-nominal FDR FWER RANK AT 
MAX 
Positive Regulation of Immune Response 26 0.6119 1.6596 0.0080 0.0884 0.6060 3191
Regulation of Molecular Function 316 0.3036 1.5693 0.0082 0.1256 0.8020 2645
Positive Regulation of RNA Metabolic Process 118 0.3576 1.5650 0.0099 0.1255 0.8150 5734
Mitochondrial Transport 20 0.4701 1.6558 0.0101 0.0871 0.6190 588
Actin Filament Organization 24 0.5038 1.6566 0.0120 0.0886 0.6150 3877
Positive Regulation of Hydrolase Activity 51 0.4937 1.6456 0.0121 0.0883 0.6470 4997
Brain Development 51 0.4229 1.6102 0.0138 0.0978 0.7220 2507
Positive Regulation of Signal Transduction 122 0.3390 1.4179 0.0145 0.1946 0.9730 4260
Cellular Cation Homeostasis 96 0.4445 1.6229 0.0150 0.0925 0.7000 4105
Mitotic Sister Chromatid Segregation 16 0.5633 1.7426 0.0154 0.0763 0.4110 2181
Sulfur Metabolic Process 35 0.4868 1.7202 0.0160 0.0741 0.4670 6219
Response to UV 25 0.4798 1.6534 0.0162 0.0868 0.6300 3222
Axon Guidance 22 0.4497 1.5003 0.0162 0.1472 0.9140 1582
Mitochondrial Organization and Biogenesis 47 0.4152 1.6108 0.0180 0.0992 0.7210 3644
ER to Golgi Vesicle Mediated Transport 18 0.6646 1.7031 0.0210 0.0747 0.5040 2953
Cation Homeostasis 99 0.4364 1.6043 0.0213 0.1007 0.7390 4105
Meiotic Cell Cycle 33 0.3765 1.5473 0.0216 0.1279 0.8490 3063
Nucleotide Excision Repair 20 0.5083 1.6299 0.0220 0.0902 0.6840 1481
Secretion by Cell 112 0.3361 1.4592 0.0220 0.1668 0.9630 3334
IkappaB Kinase NFkappaB Cascade 109 0.3689 1.4697 0.0222 0.1572 0.9410 3826
Sister Chromatid Segregation 17 0.5310 1.6345 0.0230 0.0915 0.6720 2181
Positive Regulation of Nucleobase Nucleoside 
Nucleotide and Nucleic Acid Metabolic Process 
150 0.3355 1.4911 0.0240 0.1497 0.9200 5078
Lipid Biosynthetic Process 96 0.3520 1.4942 0.0266 0.1496 0.9180 4453
Transmembrane Receptor Protein Tyrosine 
Kinase Signaling Pathway 
82 0.3016 1.3972 0.0276 0.2054 0.9840 3697
Positive Regulation of Transcription DNA 
Dependent 
116 0.3411 1.4917 0.0279 0.1506 0.9200 5734
Activation of NFkappaB Transcription Factor 18 0.4725 1.5628 0.0293 0.1254 0.8190 2277
Membrane Lipid Biosynthetic Process 48 0.4475 1.5510 0.0295 0.1275 0.8410 4213
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NAME OF GENE SET # of 
GENES 
ES NES p-nominal FDR FWER RANK AT 
MAX 
Regulation of GTPase Activity 16 0.6576 1.6401 0.0296 0.0910 0.6660 2501
Regulation of IkappaB Kinase NFkappaB Cascade 89 0.3705 1.4337 0.0297 0.1832 0.9680 3826
Regulation of Cytokine Production 25 0.4534 1.4718 0.0306 0.1613 0.9400 4084
Maintenance of Localization 22 0.4646 1.5074 0.0308 0.1486 0.9050 1919
Positive Regulation of Caspase Activity 30 0.4728 1.5094 0.0319 0.1480 0.9040 4433
Cellular Component Disassembly 33 0.3383 1.4397 0.0332 0.1803 0.9680 3644
Positive Regulation of Cytokine Production 15 0.5410 1.5394 0.0333 0.1338 0.8630 4084
Ion Homeostasis 119 0.4165 1.5551 0.0356 0.1289 0.8310 4105
Negative Regulation of Cellular Component 
Organization and Biogenesis 
28 0.4108 1.4703 0.0364 0.1597 0.9410 3877
Regulation of Intracellular Transport 25 0.5016 1.5508 0.0365 0.1260 0.8450 7129
Centrosome Organization and Biogenesis 15 0.5518 1.5332 0.0367 0.1343 0.8750 3099
Cellular Homeostasis 137 0.3971 1.5662 0.0392 0.1268 0.8100 4105
Response to Organic Substance 29 0.3699 1.4530 0.0394 0.1686 0.9640 4987
Response to Radiation 58 0.4089 1.5287 0.0395 0.1371 0.8800 3445
Leukocyte Migration 16 0.5836 1.5133 0.0397 0.1453 0.8990 1968
Negative Regulation of Cell Cycle 79 0.3370 1.4102 0.0413 0.1977 0.9800 6373
Regulation of Protein Import into Nucleus 16 0.5630 1.6280 0.0425 0.0900 0.6870 5632
Protein Amino Acid N-Linked Glycosylation 30 0.4339 1.4089 0.0426 0.1977 0.9810 704
Regulation of Nucleocytoplasmic Transport 22 0.5176 1.6371 0.0431 0.0918 0.6710 5970
Microtubule Organizing Center Organization and 
Biogenesis 
16 0.5404 1.5061 0.0441 0.1481 0.9050 3099
Positive Regulation of IkappaB Kinase NFkappaB 
Cascade 
83 0.3872 1.4363 0.0457 0.1828 0.9680 3826
Positive Regulation of Response to Stimulus 38 0.4759 1.4736 0.0482 0.1624 0.9390 3191
Response to Chemical Stimulus 305 0.3074 1.3973 0.0487 0.2067 0.9840 5257
Cellular Protein Complex Assembly 33 0.4256 1.4955 0.0494 0.1503 0.9180 3355
 
ES = enrichment score; NES = normalized enrichment score; p-nominal = nominal p-value; FDR = false discovery rate; FWER = 
family wise error rate.  Gene sets highlighted in red are further discussed. 
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Table 3.2.  Regulation of MAP Kinase Activity Genes Upregulated in shSKI NCCIT Cells. 
REGULATION OF MAP KINASE ACTIVITY 
GENE NAME GENE TITLE RANK IN GENE 
LIST 
RANK METRIC 
SCORE 
RUNNING 
ES 
CORE 
ENRICHMENT 
ADRA2C adrenergic, alpha-2C-, receptor 28 3.569720984 0.099149056 Yes 
DUSP6 dual specificity phosphatase 6 118 2.6670959 0.17067271 Yes 
CXCR4 chemokine (C-X-C motif) receptor 4 175 2.362784386 0.23489298 Yes 
SOD1 superoxide dismutase 1, soluble (amyotrophic 
lateral sclerosis 1 (adult)) 
383 1.804534674 0.27777663 Yes 
ZAK - 716 1.414972186 0.30503437 Yes 
MDFI MyoD family inhibitor 846 1.300608873 0.3367004 Yes 
DUSP22 dual specificity phosphatase 22 876 1.286507726 0.37172356 Yes 
TPD52L1 tumor protein D52-like 1 1252 1.064876556 0.38754058 Yes 
DUSP16 dual specificity phosphatase 16 1346 1.026440144 0.4128619 Yes 
GPS2 G protein pathway suppressor 2 1498 0.969061494 0.434396 Yes 
MADD MAP-kinase activating death domain 1564 0.940572977 0.4583579 Yes 
RGS4 regulator of G-protein signaling 4 1806 0.858003378 0.47339702 Yes 
CD24 CD24 molecule 1851 0.845130682 0.49546805 Yes 
MAP3K5 Mitogen-activated protein kinase kinase kinase 5 2135 0.774060726 0.5065747 Yes 
MAP4K5 mitogen-activated protein kinase kinase kinase 
kinase 5 
2584 0.679615498 0.50883806 Yes 
FGF2 fibroblast growth factor 2 (basic) 2645 0.669743836 0.5253856 Yes 
DUSP9 dual specificity phosphatase 9 3196 0.583537579 0.5211242 Yes 
ADRB2 adrenergic, beta-2-, receptor, surface 3355 0.560504258 0.5309276 Yes 
TRIB3 tribbles homolog 3 (Drosophila) 3559 0.534068823 0.53830016 Yes 
PAK1 p21/Cdc42/Rac1-activated kinase 1 (STE20 
homolog, yeast) 
3718 0.514676154 0.54681724 Yes 
“Rank in gene list” indicates the position of the gene in a ranked list of genes.  “Rank metric score” is a score used to position the 
gene in the ranked list and is computed using a “Signal2Noise” measurement that uses the difference of means scaled by the 
standard deviation. The “Running ES” is the enrichment score at this point in the ranked list of genes. Genes with a Yes value in the 
“Core enrichment” column contribute to the leading-edge subset within the gene set. This is the subset of genes that contributes 
most to the enrichment result.
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Table 3.3.  Transforming Growth Factor Beta Receptor Signaling Pathway Genes Upregulated in shSKI NCCIT Cells. 
 
TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY 
GENE NAME GENE TITLE RANK IN 
GENE LIST 
RANK METRIC 
SCORE 
RUNNING 
ES 
CORE 
ENRICHMENT 
SMAD7 SMAD, mothers against DPP homolog 7 
(Drosophila) 
32 3.454453945 0.14178942 Yes 
MAP3K7 mitogen-activated protein kinase kinase 
kinase 7 
245 2.102769136 0.22088137 Yes 
EID2 EP300 interacting inhibitor of differentiation 2 284 2.000285625 0.302254 Yes 
LEFTY1 left-right determination factor 1 494 1.66031909 0.36314425 Yes 
FMOD Fibromodulin 613 1.515063643 0.4214333 Yes 
TGFBRAP1 transforming growth factor, beta receptor 
associated protein 1 
1009 1.202226281 0.4563893 Yes 
SMAD3 SMAD, mothers against DPP homolog 3 
(Drosophila) 
1927 0.828692615 0.4563156 Yes 
TGFBR1 transforming growth factor, beta receptor I 
(activin A receptor type II-like kinase, 53kDa) 
2340 0.730790496 0.47112036 Yes 
ACVR1 activin A receptor, type I 2391 0.717254817 0.4989351 Yes 
SNX6 sorting nexin 6 2714 0.65763092 0.5140854 Yes 
 
“Rank in gene list” indicates the position of the gene in a ranked list of genes.  “Rank metric score” is a score used to position the 
gene in the ranked list and is computed using a “Signal2Noise” measurement that uses the difference of means scaled by the 
standard deviation. The “Running ES” is the enrichment score at this point in the ranked list of genes. Genes with a Yes value in the 
“Core enrichment” column contribute to the leading-edge subset within the gene set. This is the subset of genes that contributes 
most to the enrichment result.
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As expected based on SKI’s known function as a co-repressor of the 
TGFβ superfamily, genes belonging to this signaling pathway were differentially 
expressed in shSKI NCCIT cells compared to shNC NCCIT cells as well (Table 
3.3).  The expression pattern of the genes in the TGFβ superfamily may 
contribute to our finding that addition of BMP into our cell scrape assays resulted 
in an enhanced invasive phenotype of the shSKI NCCIT cells, while addition of 
TGFβ had no effect.  For example, the microarray data shows that LEFTY1 and 
SMAD7, both of which can function as inhibitors of TGFβ signaling, were 
upregulated in shSKI NCCIT cells compared to shNC NCCIT cells.  Furthermore, 
FST (follistatin), which specifically represses BMP signaling, was downregulated 
in shSKI NCCIT cells.  These data suggest that SKI may regulate the expression 
of these negative regulators of the TGFβ superfamily signaling molecules.   
The data indicate that decreased SKI may promote metastasis in testicular 
cancer.  Therefore, we were interested in differentially expressed genes that may 
be involved in cellular migration and invasion in addition to genes that may be 
involved in TGFβ superfamily signaling.  We selected certain genes from the list 
of differentially expressed genes, based on a review of the literature, which we 
believed to be potentially involved in the mechanism behind which decreased 
SKI expression promotes invasion of testicular cancer cells.  Real time PCR 
analysis was used to confirm the changes in gene expression of LEFTY1 (Figure 
3.13A), ADAMTS1 (Figure 3.13B), and CXCR4 (Figure 3.14).  Real time PCR 
analysis showed that these genes were, indeed, upregulated in shSKI NCCIT 
cells compared to shNC NCCIT cells by 1.7, 2.6, and 5.5 fold, respectively.  This 
 Table 3.4.  WNT signaling family genes identified by microarray analysis. 
 
 
 
1.7
2.2
1.7
2.1
2.4
2.6
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Downregulates the MAPK cascadeProtein phosphatase 2 (formerly 2A), 
regulatory subunit A, beta isoform
PPP2R1B
Ca(2+) dependent modifier of phosphorylation
status
Protein phosphatase 3 (formerly B2) 
gamma isoform
PPP3CC
0.5Plays a role in the light response in retinasPhospholipase C beta 4PLCB4
Stimulated in response to TGFβ and BMP; 
mediator of TGFβ superfamily transcription
Mitogen activated protein kinase kinase
kinase 7 (TGFβ activated kinase 1)
MAP3K7
G-protein coupled receptor; binds WNT protein 
and induces intracellular calcium release
Frizzled homolog 2FZD2
0.4Represses transcription in certain cells of 
genes from the TGFβ and WNT families
Patched 1 transmembrane proteinPTCH1
0.3Receptor for secreted WNT glycoproteinsFrizzled homolog 8FZD8
role in β-catenin stability
May act as a feedback repressor of β-catenin
target genes
Involved in primary axis formation in the 
mouse
Regulator of vertebrate hedgehog signaling 
pathway
Gene Function
Axis inhibitor 2 (conductin)
Transcription factor 7
WNT family member 3
Hedgehog interacting protein
Gene Description
0.5AXIN2
0.6TCF7
WNT3
HHIP
Fold 
change
Gene
Red numbers indicate increased expression and blue numbers indicate decreased 
expression in shSKI NCCIT cells compared to shNC NCCIT cells.  Gene functions 
descriptions are from Online Mendelian Inheritance in Man (OMIM) and Gene Entrez. 
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Table 3.5.  Chemokine genes identified by microarray analysis. 
 
 
 
 
 
 
 
 
 
 
 
Mediator of cellular migration; attracts 
natural killer cells to sites of infection
Alternate receptor for SDF1; involved in cell 
growth, survival, and adhesion
Recruitment of monocytes to sites of injury 
and infection
Member of chemokine family; plays a role in 
cell trafficking and immune system function
Receptor for SDF1; invovled in HIV 
infection; implicated in cancer metastasis
Gene Function
Chemokine (C-X3-C motif) ligand 1
Chemokine (C-X-C motif) receptor 7
Chemokine (C-C motif) ligand 2
Chemokine (C-C motif) ligand 26
Chemokine (C-X-C motif) receptor 4
Gene Description
CXCR4
0.5CX3CL1
CXCR7
CCL2
CCL26
Fold 
change
Gene
6.5
1.9
2.1
2.3
Red numbers indicate increased expression and blue numbers indicate decreased 
expression in shSKI NCCIT cells compared to shNC NCCIT cells.  Gene functions 
descriptions are from Online Mendelian Inheritance in Man (OMIM) and Gene Entrez. 
 
 
 Table 3.6. TGFβ superfamily signaling genes identified by microarray analysis. 
 
 
 
 
 
 
 
 
1.7
1.5
1.7
2.0
 
 
 
 
 
 
 
 
 
Stimulated in response to TGFβ and BMP; mediator of 
TGFβ superfamily transcription
Mitogen activated protein 
kinase kinase kinase 7 (TGFβ
activated kinase 1)
MAP3K7
0.5Cytokine involved in bone formation and immune 
response
Secreted phosphoprotein 1 
(osteopontin)
SPP1
0.5Negative regulator of the TGFβ superfamily FollistatinFST
0.4Negative regulator of the TGFβ superfamilySKI protooncogeneSKI
Receptor for the TGFβ superfamily signaling 
molecules
TGFβ superfamily inhibitor by inhibition of R-SMAD 
phosphorylation
TGFβ superfamily inhibitor; also involved in left-right 
polarity in early development
BMP family member; expression decreases with 
differentiation of cultured human embryonic stem cells
Gene Function
Activin A receptor, type 1C
Inhibitory SMAD 7
L-R determination factor 1
Growth differentiation factor 3
Gene Description
0.3ACVR1C
SMAD7
LEFTY1
GDF3
Fold 
Change
Gene
Red numbers indicate increased expression and blue numbers indicate decreased 
expression in shSKI NCCIT cells compared to shNC NCCIT cells.  Gene functions 
descriptions are from Online Mendelian Inheritance in Man (OMIM) and Gene Entrez. 
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Figure 3.13.  LEFTY1 and ADAMTS-1 expression in shSKI NCCIT cells compared 
to shNC NCCIT cells.  Real time PCR analysis comparing LEFTY1 (A) and ADAMTS1 
(B) expression in shSKI NCCIT cells and shNC NCCIT cells.  RNA levels were 
normalized to 18S RNA.  Data represents six individual trials and was analyzed using 2-
∆∆Ct method; error bars indicate the 95% confidence interval. 
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confirmed the microarray SAM results showing that LEFTY1, ADAMTS1, and 
CXCR4 were upregulted in shSKI NCCIT cells by 1.7, 2.1, and 6.5 fold, 
respectively. 
 
SMAD Binding Elements in Promoters of Target Genes 
In order to determine if potential target genes of SKI that were identified by 
microarray analysis were transcriptionally regulated by SMADs, promoter 
analysis of specific genes was performed to identify the presence of BMP and/or 
TGFβ regulatory elements.  BMP and TGFβ signaling is transmitted inside the 
cell by SMADs.  R-SMADs, SMAD 1, 5, and 8, are phosphorylated in response to 
BMP signals, while R-SMADs, SMADs 2 and 3, are phosphorylated in response 
to TGFβ signals.  These phosphorylated R-SMADs form a complex with the co-
SMAD, and these complexes are able to initiate target gene transcription by 
binding to the promoter region with additional co-factors (Massague and Wotton, 
2000).  SKI is known to repress both BMP and TGFβ signaling by interfering with 
SMAD-mediated gene transcription (Akiyoshi, et al., 1999; Luo, et al., 1999; 
Stroschein, et al., 1999).  Cell scrape migration experiments revealed that 
addition of BMP to SKI-knockdown NCCIT cells resulted in an enhanced invasive 
phenotype, while addition of TGFβ had no effect.  Therefore, we were interested 
in identifying SKI-responsive genes that are regulated by BMP.  The presence of 
SMAD 1/5/8 binding elements in the promoter region of a gene would be 
evidence of regulation by BMP.  TGFβ-regulated SMAD binding elements were 
also considered to determine the specificity of gene regulation.  
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A literature search revealed several potential SMAD regulatory elements 
for both BMP and TGFβ responsive genes.  GCCGnCGC has been reported as a 
SMAD1 binding motif (Benchabane and Wrana, 2003; Ishida, et al., 2000; Kim, et 
al., 1997; Kusanagi, et al., 2000).  Kusanagi, et. al. (2000) provided evidence that 
a reporter gene construct containing multiple copies of this motif was stimulated 
in response to BMP, but not in response to TGFβ or activin.  It has also 
previously been reported that SMAD1 binds to this sequence in the SMAD7 
promoter (Benchabane et al., 2003).   
GTCTAGAC has been shown to be a SMAD5 binding sequence (Li, et al., 
2001; Zawel, et al., 1998) and has also been reported to be TGFβ-responsive 
(Stopa, et al., 2000).  The CAGACA motif is also not specific to BMP-activated 
SMADs.  It has been reported to be BMP-responsive in the ID1 promoter, and 
both SMAD4 and SMAD1 can bind this sequence (Katagiri, et al., 2002).  This 
element was also identified in the promoter of JunB, and expression of JunB was 
induced by TGFβ, activin, and BMP (Jonk, et al., 1998).  However, Dennler et al. 
(1998) reported that this sequence was specific to TGFβ and activin responses.   
Several other TGFβ response sequences have been reported.  Song et al. 
(1998) reported that both SMAD3 and SMAD4 bind to the motif 
AGACAAGGTTGT in the promoter of human type 1 plasminogen activator 
inhibitor (PAI1), and activate transcription in response to TGFβ.  
ACAGACAGACAC has been identified as a binding site for the SMAD3-SMAD4 
complex in the promoter of JunB and is TGFβ responsive (Wong 1999).  
Additionally TGFβ has been shown to enhance the expression of type VII 
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collagen (COL7A1) by inducing the binding of the SMAD3-SMAD4 complex to 
the sequence, GCCCACCAGACAGATGGCTGAATCACAGGAGTGGCCGGCG 
GGACCCATGGCCT within the promoter of COL7A1 (Kon et al., 1999, 
Vindevoghel et al., 1998).  Hua et al. (1998, 1999) identified two sequences in 
the PAI1 promoter that contained multiple AGAC SMAD-binding element repeats, 
AGACAGACAAAACCTAGACAATCACGTGGCTGGCTGCATGCCCTGTGGCTG
TTGGGC and CCTAGACAGACAAAACCTAGACAATCACGTGGCTGG; these 
sequences also contain a binding site for transcription factor µE3 (TFE3), which 
was determined to be an essential binding partner in the SMAD transcriptional 
complex for TGFβ-induced transcription of PAI1 (Hua et al., 1999).  Lindemann 
et al. (2001) described a TGFβ-responsive SMAD3-SMAD4 binding element in 
the promoter of parathyroid hormone-related protein (PTHrP), GAGGAGGTAGA 
CAGACAGCTATGT, which aso contained multiple AGAC SMAD-binding 
element repeats, as well as an Ets transcription factor binding domain.  Finally, 
Shi et al. (1998) performed cocrystallization studies and electrophoretic mobility 
shift assays to identify a the SMAD3 DNA binding element, AGTATGTCTAGAC 
TGA.   
Using the Motif Locator tool on the MOtif Discovery (MoD) tools website 
(http://159.149.109.9/modtools/; Pavesi 2006), the promoter sequences of 
specific genes, chosen based on our microarray analysis and previous reports 
associating these genes with metastasis, migration, or TGF superfamily 
signaling, were searched for the presence of each of the SMAD binding elements 
(Table 3.7).  ADAMTS1, CXCR4, LEFTY1, SMAD7, MAP3K7, and WNT3 were 
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all upregulated in SKI knockdown cells according to our microarray data.  CXCR4, 
SMAD7, and WNT3 promoters contained all three of the BMP response elements.  
CXCR4 and SMAD7 both contained multiple copies of each of the three BMP 
response elements, and it has been reported that multiple copies of the 
consensus sequence promotes SMAD binding (Ishida, et al., 2000; Kusanagi, et 
al., 2000).  The WNT3 promoter had multiple copies of the two motifs that are not 
BMP-specific, and only one copy of the GCCGnCGC motif.  The MAP3K7 
promoter contained multiple copies of the BMP-specific motif and the non-
specific motif, CAGACA.  The ADAMTS1 promoter contained multiple copies 
both the GTCTAGAC and the CAGACA motif; these two motifs are responsive to 
both TGFβ and BMP.  The LEFTY1 promoter contained multiple copies of the 
TGFβ/BMP-response element CAGACA motif as well as multiple copies of the 
BMP-specific GCCGnCGC motif.  The ADAMTS1 promoter was the only 
promoter that contained TGFβ-specific response element, the ACAGACAGACAC 
motif.   
FST (follistatin) and SPARC (secreted protein acidic and rich in cysteine) 
were both downregulated in SKI knockdown cells compared to control cells.  The 
FST promoter contained multiple copies of both of the TGFβ/BMP response 
motifs as well as the BMP-specific motif.  The SPARC promoter also contained 
multiple copies of both of the TGFβ/BMP response motifs, but the BMP-specific 
motif was not present.   
SMAD6 was not differentially expressed in shSKI compared to shNC 
NCCIT cells according to our microarray data; however its expression has  
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Table 3.7.  SMAD Promoter Elements in Potential Target Genes. 
 ADAMTS1 CXCR4 FST LEFTY1 MAP3K7 MMP9 SMAD6 SMAD7 SPARC WNT3 
BMP 
Elements 
GTCTAGAC* + (2) + (4) + (6) - - + (6) + (2) + (4) + (6) + (2) 
CAGACA** + (69) + (84) + (66) + (78) + (30) + (66) + (79) + (72) + (113) + (92)  
GCCGnCGC - + (13) + (63) + (29) + (2) - + (71) + (2) - + (1) 
TGFβ 
Elements 
GTCTAGAC* + (2) + (4) + (6) - - + (6) + (2) + (4) + (6) + (2) 
AG(C/A)CAGACA** + (69) + (84) + (66) + (78) + (30) + (66) + (79) + (72) + (113) + (92) 
AGACAAGGTTGT - - - - - - - - - - 
ACAGACAGACAC + (1) - - - - - - - - - 
GCCCACCAGACA
GATGGCTGAATCA
CAGGAGTGGCCG
GCGGGACCCATG
GCCT 
- - - - - - - - - - 
AGACAGACAAAAC
CTAGACAATCACG
TGGCTGGCTGCAT
GCCCTGTGGCTG
TTGGGC 
- - - - - - - - - - 
CCTAGACAGACAA
AACCTAGACAATC
ACGTGGCTGG 
- - - - - - - - - - 
GAGGAGGTAGAC
AGACAGCTATGT 
- - - - - - - - - - 
 
AGTATGTCTAGAC
TGA 
- - - - - - - - - - 
* and ** sequences have been described to be both BMP and TGFβ responsive.  + indicates the response element was present in 
the promoter sequence; - indicates the response element was not present.  Numbers in ( ) indicate the number of times the response 
element was detected within the promoter sequence.
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served as a positive control.  The SMAD6 
both of the TGF
matrix remodeling protein, and, thus, 
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SDF/CXCR4:  Role in invasion of SKI-knockdown cells 
 
upregulate
its signaling ligand, SDF1, have previ
are also important regulators of germ ce
determine if this upregulation of CXCR4 
potential se
cells comp
analys
cells compared to shNC cells, however, addi
did not significantly alt
NCCIT cells.  SDF1, the signa
shown to be upregulat
ibed to be regulated by BMP (Ishida, et al., 2000), and thus 
promoter contained multiple copies of 
β/BMP response motifs and the BMP-specific motif.  MMP9 is a 
thought to be involved in metastasis.  
ssed in shSKI compared to shNC NCCIT 
ding to our microarray data, and, therefore, appears to be SKI non-
  However, it also contained multiple copies of the BMP-specific motif 
β/BMP response motif, CAGACA.   
According to the microarray data, CXCR4 mRNA expression was 
d in shSKI NCCIT cells compared to shNC NCCIT cells.  CXCR4 and 
ously been implicated in metastasis, and 
ll migration.  Therefore, we sought to 
contributes to the increased invasive 
en in SKI-knockdown NCCIT cells.   
The microarray results that CXCR4 mRNA is upregulated in shSKI NCCIT 
ared to shNC NCCIT cells were first confirmed using real time PCR 
is (Figure 3.14).  CXCR4 is, indeed, upregulated 5.5 fold in shSKI NCCIT 
tion of BMP or its inhibitor, noggin, 
er the levels of CXCR4 mRNA in either shSKI or shNC 
ling ligand partner of CXCR4, has previously been 
ed by BMP (Yang, et al., 2008).  However, at the 
concentration used, real time PCR showed no change in SDF1 mRNA 
expression in response to treatment of either shNC or shSKI NCCIT cells with 
BMP4 (Figure 3.15).  This indicates that, at the concentrations used, BMP is not 
able to induce transcription of CXCR4 or SDF1 in either shNC or shSKI NCCIT 
cells.   
 Since CXCR4 is increased in shSKI NCCIT cells compared to shNC 
NCCIT cells, Matrigel invasion assays were used to assess whether this 
upregulation of CXCR4 enhanced the invasive phenotype of the shSKI NCCIT 
cells.  SDF1, the signaling ligand for CXCR4, and/or AMD3100, a potent and 
specific inhibitor of CXCR4 (Broxmeyer, et al., 2005; Hatse, et al., 2002), were 
added to the companion wells of the Matrigel invasion chambers to determine 
their effects on the invading cells.  Addition of 25 ng/mL SDF1 to the companion 
wells significantly increased the invasion of shSKI NCCIT cells, but had no effect 
on the invasion of shNC NCCIT cells (Figure 3.16).  When 50 ng/mL AMD3100 
was added in combination with SDF1, it was able to significantly reduce the 
effects of SDF1, almost to the level of invasion seen in shNC NCCIT cells (Figure 
3.16).  Addition of 50 ng/mL AMD3100 alone significantly reduced the level of 
invasion in shSKI NCCIT cells to the level of invasion seen in shNC NCCIT cells.   
However, addition of AMD3100 to shNC NCCIT cells did not affect invasion of 
these cells, indicating that AMD3100, alone, does not affect invasion.  These 
data suggest that the CXCR4/SDF1 signaling partners enhance the invasive 
phenotype of NCCIT cells with reduced levels of SKI.   
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Figure 3.14.  CXCR4 mRNA expression in shNCCIT cells treated with BMP and/or 
noggin.  Real time PCR analysis comparing CXCR4 mRNA expression in shNC NCCIT 
cells ± 10ng/mL BMP, ± 0.1µg/mL noggin compared to shSKI NCCIT cells ± 10ng/mL 
BMP, ± 0.1µg/mL noggin.  RNA levels were normalized to 18S RNA.  Data represents 
three individual trials and was analyzed using 2-∆∆Ct method; error bars indicate the 95% 
confidence interval. 
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Figure 3.15.  SDF1 mRNA expression in shNCCIT cells treated with BMP and/or 
noggin.  Real time PCR analysis for SDF1 mRNA in shNC NCCIT cells ± 10ng/mL BMP, 
± 0.1µg/mL noggin compared to shSKI NCCIT cells ± 10ng/mL BMP, ± 0.1µg/mL noggin.  
RNA levels were normalized to 18S RNA.  Data represents three individual trials and 
was analyzed using 2-∆∆Ct method; error bars indicate the 95% confidence interval.  
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Figure 3.16.  Role of CXCR4/SDF1 in the invasive potential of shNCCIT cells.  Bar 
graph representing the number of migrating cells in Matrigel invasion assays using shNC 
NCCIT cells and shSKI NCCIT cells ± 25ng/mL SDF, ± 50ng/mL AMD 3100 to the 
medium in the companion wells. Data represents five trials; error bars indicate SEM; 
Groups labeled A, B, and C, and D are each significantly different from each other with p 
< 0.05. 
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 CHAPTER IV 
 
DISCUSSION 
 
SKI has previously been described as an oncogene based on its ability to 
transform avian fibroblasts (Colmenares and Stavnezer, 1989).  However, the 
role of SKI in mammalian tumorigenesis is not yet fully characterized.  The 
available literature on SKI suggests that SKI plays dual roles in tumorigenesis 
and that SKI’s involvement in cancer progression may be cell type and context 
dependent.  For example, SKI has been shown to promote proliferation in 
pancreatic cancer cells (Heider, et al., 2007), yet other studies have shown that 
SKI does not affect the rate of proliferation in lung and breast cancer cell lines 
(Le Scolan, et al., 2008; Zhu, et al., 2007).  In addition, various studies have 
shown that SKI is over-expressed in some tumor types including melanoma, 
esophageal, colon, and pancreatic cancer (Buess, et al., 2004; Fukuchi, et al., 
2004; Heider, et al., 2007; Reed, et al., 2005). In contrast, data presented by 
Shinagawa et. al.(2001), showed that mice heterozygous for a null mutation in 
the SKI gene were more susceptible to tumorigenesis, which suggests that SKI 
may function as a tumor suppressor. 
The data presented within this text supports the idea that SKI may play 
different roles in tumorigenesis in different cell types.  Analysis of a panel of 
human cell lines for SKI expression showed that SKI expression varies widely in 
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different types of cancer.  In support of previous data (Reed, et al., 2005), SKI 
expression increases in progressing stages of melanoma, with the highest 
expression seen in WM9 metastatic melanoma cells.  On the other hand, SKI 
expression appears to be lower in T47D ductal carcinoma cells compared to 
HMEC normal breast cells; while the level of SKI expression in MCF7 mammary 
adenocarcinoma cells was very similar to that of HMEC cells.  Both of these cell 
lines were derived from metastatic pleural effusions, and are described as weakly 
metastatic in vitro (Lacroix and Leclercq, 2004).  HCT116 cells, derived from a 
primary colorectal carcinoma (Brattain, et al., 1981), expressed high levels of SKI, 
while A549 primary lung carcinoma cells have very low SKI expression.  The 
level of SKI expression in NCCIT embryonal carcinoma cells, derived from a 
mediastinal metastasis, was intermediate compared to other cell lines studied.  
Taken together, these data indicate that SKI may, indeed, act as an oncogene in 
some tissues, but may play an anti-tumorigenic role in others. 
The data presented here indicate that SKI expression is decreased in 
human testicular germ cell tumors compared to normal testis samples.  Previous 
studies have shown that CCND2 mRNA and protein expression are increased in 
TGCT samples compared to normal testis (Bartkova, et al., 1999; Houldsworth, 
et al., 1997; Schmidt, et al., 2001).  Our real time PCR data confirms this 
observation, and CCND2 served as a positive control in these experiments.  SKI 
mRNA expression decreased in the same tumor samples, while SNO was not 
differentially expressed.  Furthermore, our data also show that proliferation is not 
affected by SKI expression in NCCIT testicular cancer cells.  However, the level 
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of SKI expression in NCCIT cells does influence the ability of these cells to 
migrate and invade since experimentally reducing SKI expression in NCCIT cells 
resulted in increased invasive potential. These data suggest that in testicular 
germ cell tumors SKI does not act as an oncogene, but rather promotes tumor 
progression to a metastatic state. 
SKI has been identified as a negative regulator of the TGFβ superfamily.  
Previous data indicate that TGFβ has diverging roles in tumorigenesis.  While 
TGFβ may act as a tumor suppressor in the early stages of tumorigenesis by 
inhibiting cellular proliferation, evidence suggests that TGFβ superfamily 
signaling promotes cancer invasion and metastasis, permitting cancer 
progression (Derynck, et al., 2001; Le Scolan, et al., 2008; Leivonen and Kahari, 
2007; Rothhammer, et al., 2005; Tang, et al., 2003; Wakefield and Roberts, 2002; 
Zhu, et al., 2007).   A recent study reported that forced over-expression of SKI in 
JygMC(A) mouse mammary carcinoma cells decreased the metastatic potential 
of these cells in vivo (Azuma, et al., 2005).  In accordance with this finding, Le 
Scolan et al. (2008) recently reported that experimentally reducing SKI 
expression in breast and lung cancer cell lines promoted TGFβ-mediated cancer 
metastasis.  Similarly, we found that reducing SKI expression in NCCIT testicular 
cancer cells resulted in a more invasive phenotype.  In the same study by Le 
Scolan et. al. (2008), they found that SKI was abundantly expressed in a panel of 
metastatic melanoma cells and breast cancer cell lines. We also found that SKI 
expression is high in metastatic melanoma and variable in other cell lines derived 
from metastatic and primary tumors.  These data suggest that the role of SKI in 
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tumorigenesis is complex and may be dependent on the tissue type and other 
factors present within the cell and microenvironment as well as the levels of SKI.  
The data presented in this body of work support the role of SKI as an 
inhibitor of metastasis in TGCTs.  In human embryonal carcinoma NCCIT cells, 
decreasing the expression of SKI resulted in enhanced migration and invasion, 
while forcing the expression of SKI significantly reduced the invasive potential of 
these cells, as assessed by both cell scrape assays and Matrigel invasion assays. 
Interestingly, it has also been reported that experimentally reducing SNO, 
another member of the SKI gene family, in breast and lung cancer cell lines 
resulted in increased metastatic potential in these cells in response to TGF (Zhu, 
et al., 2007).  In contrast to reduced SKI levels in TGCTs, our data show that 
SNO expression was not significantly different in TGCTs and normal testis 
samples, indicating that SKI, but not SNO, may be involved in testicular cancer 
progression and metastasis.  These data, taken together with the tumor data 
showing decreased SKI expression in human TGCTs, suggest that SKI may 
function to prevent testicular cancer metastasis by repressing signals from the 
TGFβ superfamily. 
In the current experiments, decreased SKI expression was sufficient to 
promote invasion in the testicular cancer cell lines without the addition of growth 
factors, suggesting that the cells may be responding to an autocrine loop of 
TGFβ superfamily signaling.  Although the SKI-knockdown cells were cultured in 
low-serum medium, it is also possible that factors in the serum may contribute to 
the increased metastasis observed in these studies.  In addition to being a co-
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repressor of the TGFβ superfamily, SKI is able to interact with transcription 
factors other than SMADs, including MyoD (Engert, et al., 1995) and nuclear 
factor I (NF1) (Tarapore, et al., 1997), and therefore, the increase in invasive 
potential seen in SKI-deficient cells could also partially be due to changes in 
gene expression that are independent of TGFβ superfamily signaling. 
It is possible that the level of closure observed in the cell scrape assays 
could be due in part to proliferation of the cells at the border of the scrape; 
however, it is unlikely that the closure could be due to proliferation alone.  The 
rate of proliferation in the SKI-knockdown cells was not significantly different from 
that of the control treated cells. The NCCIT cells have a population doubling time 
of approximately 18 hours (data not shown).  Migration was observed over a 20 
hour time period, thus the NCCIT cells barely had time to complete one round of 
division.  In the cell scrape assays, the distance that cells have migrated into the 
scrape area is greater than one cell diameter in thickness at 20 hours compared 
to the scrape at 0 hours.  Furthermore, the data from the cell scrape assays are 
complemented by the Matrigel invasion assays, which require cells to migrate 
through a membrane coated with Matrigel. Therefore, cellular proliferation cannot 
fully account for the percentage closure observed.   
There is further evidence to suggest that TGFβ superfamily signaling 
molecules may be involved in metastasis of testicular cancer.  The TGFβ 
superfamily has been implicated in the allocation and migration of primordial 
germ cells (PGCs), the precursors to adult germ cells, during development.  
BMP4 and BMP8b, members of the TGFβ superfamily, have been shown to be 
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required for the allocation of PGCs in the mouse and also appear to be involved 
in PGC migration (Dudley, et al., 2007; Lawson, et al., 1999; Pesce, et al., 2002; 
Ying, et al., 2000; Ying, et al., 2001).  Additionally, TGFβ1 has a chemotropic 
affect on PGCs, and, thus, may be involved in germ cell migration (Godin and 
Wylie, 1991).  This suggests that loss of function of SKI may contribute to the 
metastasis of testicular cancer by allowing uncontrolled signaling from the TGFβ 
superfamily, which may function to increase the migration of TGCTs through a 
chemotropic effect, promoting the dissemination of tumor cells.  It has been 
proposed that testicular cancer metastasis is related to the migration process of 
PGCs, partially based on common sites of metastasis being related to the path of 
migrating PGCs (Chaganti, et al., 1994).  Thus genes involved in PGC migration 
are of interest as potential target genes promoting testicular cancer metastasis.   
The data presented within text show that decreased SKI expression 
appears to promote a more invasive phenotype in NCCIT cells.  Since SKI is 
known to be a co-repressor of the TGFβ superfamily, the next goal of this 
research was to determine if loss of function of SKI contributes to testicular 
cancer metastasis by allowing uncontrolled signaling from the TGFβ superfamily.  
To address this question, we studied the response of SKI- knockdown NCCIT 
cells to both TGFβ and BMP to determine if these members of the TGFβ 
superfamily further enhanced the increased invasive potential seen in NCCIT 
cells with reduced SKI expression. 
TGFβ has been shown to promote metastasis in the later stages of some 
cancers (Jakowlew, 2006; Tang, et al., 2003).  Le Scolan et. al. (2008) reported 
 89
that SKI plays an antitumorigenic role in MDA-MB-231 breast cancer cells and 
A549 lung cancer cells.  Expression of SKI was high in MDA-MB-231 breast 
cancer cells and low in A549 lung cancer cells.  Experimentally reducing levels of 
SKI in these cells resulted in an enhanced ability of these cells to invade.  
Furthermore, they found that treating these cells with TGFβ reduced SKI 
expression through E3 ubiquitin ligase-mediated degradation, and they suggest 
that this pathway plays an important role in the ability of SKI to repress 
metastasis.  Taken together, these data suggest that reduced levels of SKI in 
cancer cells may promote metastasis by allowing unregulated signaling of TGFβ.  
However, our data shows that addition of TGFβ to shSKI NCCIT cells did not 
affect the migration of these cells in vitro.  Furthermore, the addition of TGFβ 
blocking antibody also did not affect the migration of shSKI NCCIT cells.  This 
indicates that in NCCIT cells with reduced SKI expression, TGFβ does not affect 
migration.   
There are several possible reasons to explain why TGFβ may not have an 
effect on the migration of SKI-deficient NCCIT cells.  One possible explanation is 
that the components of the TGFβ signaling pathway are not present or are not 
active in NCCIT cells.  This prompted us to look at the activity of the TGFβ 
pathway in these cells by investigating SMAD phosphorylation.  TGFβ signals 
through intracellular transcription factors, SMAD2 and SMAD3.  When TGFβ 
activates the cell surface receptors, these receptors induce the phosphorylation 
of SMAD2 and SMAD3, which then form a complex with SMAD4.  This complex 
is able to translocate to the nucleus and activate transcription of TGFβ target 
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genes (Luo, 2003).  Western blots showed that SMAD2 is expressed in shNCCIT 
cells.  However, even after a two hour incubation with TGFβ, phosphorylated 
SMAD2 (p-SMAD2) was only detected at very low levels.  Based on microarray 
data, ELISA, and Superarray PCR data (data not shown) other components of 
the TGFβ signaling pathway, including TGFβ receptors and TGFβ, are expressed 
in NCCIT cells.  Treatment with TGFβ did result in a slight induction of p-SMAD2. 
However, because this induction was only slight, it is possible that an inhibitor of 
TGFβ may be preventing strong signaling from this pathway, even in the absence 
of SKI.   
LEFTY1 is an inhibitor of the TGFβ superfamily which functions by 
preventing SMAD phosphorylation (Ulloa, et al., 2001).  LEFTY1 was shown via 
the microarray analysis, and confirmed by real time PCR analysis, to be 
upregulated in shSKI NCCIT cells compared to shNC NCCIT cells.  Increased 
LEFTY1 expression may contribute to the lack of response seen in shSKI NCCIT 
cells treated with TGFβ.  TGIF, which interacts with SMAD2 and SMAD3 to 
prevent TGFβ signaling, was also shown to be expressed in shSKI NCCIT cells 
by Superarray PCR analysis (data not shown).  In addition, the inhibitory SMAD, 
SMAD7, was also increased in shSKI NCCIT cells compared to shNC NCCIT 
cells according to microarray analysis.  Although SMAD7 has been shown to 
interfere with both TGFβ and BMP signaling, there may be multiple inhibitors 
acting against TGFβ signaling that weaken that branch of the TGFβ superfamily 
while allowing BMP signaling.  Finally, our data showed that SKI mRNA 
expression is decreased in TGCTs compared to normal testis samples, but SNO 
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mRNA levels were not altered.  Both SKI and SNO have been shown to repress 
TGFβ signaling (Akiyoshi, et al., 1999; Luo, et al., 1999), but only SKI has been 
shown to interfere with BMP signal transduction (Takeda, et al., 2004; Wang, et 
al., 2000).  This suggests that SNO may also function to inhibit TGFβ signaling, 
even in the absence of SKI, but BMP signaling could still be active.   
In addition to inhibiting TGFβ signaling, SKI also functions as a co-
repressor of BMP, another member of the TGFβ superfamily, through its 
interaction with SMAD1/5/8 – SMAD4 complex (Takeda, et al., 2004; Wang, et al., 
2000).  Therefore, we next tested the effect of adding BMP to our cell scrape 
assays to determine if this enhanced migration in SKI knockdown NCCIT cells.  
When exogenous BMP4 was added to cell scrape assays, migration was 
significantly increased in shSKI NCCIT cells, but not in shNC NCCIT cells.  
Furthermore, addition of noggin, an extracellular BMP inhibitor, was able to 
reverse the effects of BMP seen in shSKI cells, and addition of noggin alone 
reduced migration in shSKI NCCIT cells back to the level of migration seen in 
untreated shNC NCCIT cells.  Noggin treatment, alone, also slightly reduced 
migration in shNC NCCIT cells.  This suggests that treating both shSKI and 
shNC NCCIT cells with noggin may inhibit the effects of any endogenous BMP 
expressed by NCCIT cells.  This data indicates that reduced levels of SKI in 
NCCIT cells enhance the migration of these cells by allowing increased BMP 
signaling.  
The activity of the BMP pathway was also considered by testing the cells 
for the induction of phosphorylated R-SMADs.  BMP signals are transmitted 
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intracellularly by SMADs 1, 5, and 8 (Yamashita, et al., 1996).  Activation of cell 
surface receptors by BMP results in phosphorylation of SMAD1/5/8, which then 
forms a complex with SMAD4, and this complex activates the transcription of 
BMP target genes.  ShSKI and shNC NCCIT cells incubated with BMP4 for two 
hours showed strong expression of phospho-SMAD1/5/8 (p-SMAD1/5/8).  
Phosphorylation of SMAD1/5/8 was inhibited in the presence of noggin.  This 
indicates that the BMP pathway is active in shNCCIT cells.  As expected, 
phosphorylation of SMAD1/5/8 was not affected by SKI expression because 
SKI’s inhibition of BMP signaling acts downstream of SMAD phosphorylation.  
The data collected on the effects of BMP in SKI-deficient NCCIT cells suggest 
that the BMP family may be a potential target to consider in the development of 
new therapies to treat patients with metastatic testicular cancer.  However, 
further research is necessary to determine the efficacy of using BMP inhibitors to 
prevent testicular cancer metastasis in vivo. 
Because SKI functions primarily as a transcription factor and co-repressor, 
microarray analysis was performed to identify potential target genes with altered 
expression in SKI-deficient cells that may contribute to an invasive phenotype 
and play a role in testicular cancer progression.  As expected, one of the gene 
sets identified through microarray analysis by GSEA as being upregulated in SKI-
knockdown cells compared to control cells was the “Transforming Growth Factor 
Beta Receptor Signaling Pathway” (Table 3.3).   Several genes involved in TGFβ 
superfamily signaling were also identified by SAM analysis as being differentially 
expressed in shSKI NCCIT cells compared to shNC NCCIT cells (Table 3.6).  
 93
SKI is a co-repressor of the TGFβ superfamily, therefore, it would be expected 
that some members of this signaling pathway would be affected by depleting SKI.  
In studying the results from the GSEA and SAM analyses, some common genes 
were identified as being upregulated in SKI-knockdown NCCIT cells, including 
SMAD7, LEFTY1, and MAP3K7.  As previously discussed, SMAD7 and LEFTY1 
are both inhibitors of TGFβ signaling, thus increased expression of these genes 
may contribute to the lack of response seen with the addition of TGFβ to shSKI 
NCCIT cells in the cell scrape migration assays.   
“Regulation of MAP kinase activity” was one of only three gene sets 
identified by GSEA that met not only the dual criteria of FDR less than 0.25 and 
nominal p-value less than 0.05, but also the more stringent test of FWER less 
than 0.05. Interaction between the MAPK and BMP pathways has previously 
been shown to be involved in cell fate determination.  FGF8 and IGF2, both of 
which activate MAPK signaling, have been shown to inhibit nuclear localization of 
the BMP-responsive SMAD1; this interaction can function to inhibit BMP 
signaling, preventing differentiation down the mesoderm lineage and favoring 
neural differentiation (Massague, 2003).  However, these specific genes were not 
identified through GSEA as being enriched in the SKI-knockdown cells.  Since 
MAPK signaling can function to inhibit SMAD1-mediated transcription by blocking 
nuclear localization of SMAD1, it is possible that upregulation of MAPK signaling 
may be a compensation mechanism for the increased activity of the BMP 
pathway in SKI-knockdown cells.  Activation of the Ras/MAPK pathway has also 
been shown to inhibit SMAD2 nuclear localization, preventing TGFβ signaling 
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(Massague, 2003).  This suggests that upregulation of MAPK signaling in SKI-
knockdown cells may contribute to the lack of response seen with the addition of 
TGFβ to the shSKI NCCIT cells.  A specific link between SKI and the MAPK 
pathway has not been shown.  Thus our data suggest that there may be further 
interaction between MAPK signaling and TGFβ superfamily signaling.   
One of the genes identified by GSEA as belonging to the gene group 
“Regulation of MAP kinase activity” was CXCR4.  CXCR4 was also shown to be 
upregulated by SAM analysis in shSKI NCCIT cells compared to shNC NCCIT 
cells, and this increased expression was confirmed via real time PCR.  
CXCR4/SDF1 signaling partners have previously been shown to be involved in 
both PGC migration (Doitsidou, et al., 2002; Molyneaux, et al., 2003) and 
testicular cancer metastasis (Gilbert, et al., 2009); SDF1 acts as a 
chemoattractant for the germ cells and cancer cells, which express CXCR4.  
SDF1 is known to be expressed in sites of the body to which testicular cancer 
frequently metastasizes, including lymph nodes, lung, liver, and brain (Gilbert, et 
al., 2009; Muller, et al., 2001), further implicating these signaling partners as 
potential mediators of testicular cancer metastasis.   
We were interested to know if CXCR4 is a possible target of BMP 
signaling.  Real time PCR analysis showed that, at the concentration used, 
CXCR4 expression was not significantly changed when shNC or shSKI NCCIT 
cells were incubated with either BMP or noggin.  These data suggest that the 
increase in CXCR4 expression in shSKI NCCIT cells compared to shNC NCCIT 
cells may be independent of BMP signaling.  SDF1, the signaling ligand partner 
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of CXCR4, has previously been shown to be upregulated by BMP (Yang, et al., 
2008).  However, at the concentration used, real time PCR showed no change in 
SDF1 mRNA expression in response to treatment of either shNC or shSKI 
NCCIT cells with BMP4.   
Although CXCR4 and SDF1 expression were not affected by BMP4 
treatment of shNCCIT cells, CXCR4 expression was upregulated in SKI-
knockdown NCCIT cells compared to NCCIT cells stably transfected with the 
negative control shRNA vector.  Thus, the effect of SDF1 on the ability of these 
cells to invade in vitro was tested using a Matrigel invasion assay.  Addition of 
SDF1 to the companion wells of the Matrigel invasion chambers significantly 
enhanced the invasion of shSKI NCCIT cells but had no effect on shNC NCCIT 
cells.  Furthermore, AMD3100, a potent and specific inhibitor of CXCR4 
(Broxmeyer, et al., 2005; Hatse, et al., 2002), was able to reverse the effects of 
SDF1 in shSKI NCCIT cells, but, again, no effect was seen in shNC NCCIT cells.  
These data provides good evidence that increased expression of CXCR4 in SKI-
knockdown NCCIT cells contributes to the enhanced invasive phenotype seen in 
these cells.   
Previous data have implicated the CXCR4/SDF1 signaling partners in 
testicular cancer metastasis (Gilbert, et al., 2009).  Our data support the role of 
CXCR4/SDF1 signaling in testicular cancer metastasis, and our data also adds 
additional information on the upstream regulation of CXCR4 expression, which 
gives a better overall picture of the mechanism by which testicular cancer cells 
may acquire a more invasive phenotype.  These data, taken together with 
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previous data showing that BMP also enhances migration in shSKI NCCIT cells, 
suggests that decreased SKI expression in NCCIT testicular cancer cells 
promotes migration and invasion through both BMP-dependent and BMP-
independent pathways.  This collection of data also implicates CXCR4 and SDF1 
as potential targets for testicular cancer therapies.  Again, further research is 
needed to determine the effects of using inhibitors CXCR4 and SDF1 signaling in 
vivo.   
Several genes belonging to the WNT signaling family were identified by 
SAM analysis as being differentially expressed in shSKI compared to shNC 
NCCIT cells.  Interaction between SKI and the WNT family has previously been 
shown (Chen, et al., 2003).  In melanoma cells, forcing the expression of SKI 
stimulated cellular proliferation by activating the WNT pathway.  Chen et. al. 
(2003) found that SKI binds to FHL2 (four-and-a-half lim domains 2), which binds 
β-catenin and can either repress or activate β-catenin, depending upon the cell 
type (Martin, et al., 2002).  Forced SKI expression resulted in the activation of 
FHL2 and β-catenin-responsive gene promoters.  These data suggest that, in 
addition to mediating TGFβ superfamily target gene transcription, SKI can act as 
a transcriptional regulator of the WNT signaling family by acting as a binding 
partner for FHL2.  This could be a BMP-independent mechanism for gene 
regulation in our system which merits further exploration. 
While several individual genes and gene families of interest were identified 
as potential participants in testicular cancer metastasis by microarray analysis, 
there are some notable absences in groups of genes that one might expect to be 
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involved in the observed invasive phenotype.  For example, GSEA did not reveal 
significant differences in gene sets such as “Cell migration” and “Cell-cell 
adhesion”; nor were there any significant changes in matrix metalloproteinases 
(MMPs).  Genes in these groups would likely be involved in invasion and 
metastasis, so one might expect these sets to be significantly altered in the 
shSKI NCCIT cells, which had enhanced invasive potential.  There are several 
possible explanations for the absence of a significant difference in these gene 
sets.  (1) There are limitations in the GSEA software in that it is not yet capable 
of identifying significant changes in gene sets that have both up- and down-
regulated genes.  The software currently only recognizes significantly up-
regulated genes.  It is quite possible that certain genes involved in the prevention 
of cellular migration, for example, may be down-regulated in SKI-knockdown 
cells, contributing to the enhanced invasive phenotype.  However, these changes, 
though potentially important to the observed phenotype, would not be recognized 
by GSEA.  (2) The gene sets used in this software are constructed based on the 
available literature.  They are not all-inclusive, and it is possible that there are 
additional genes involved in cellular migration or cell-cell adhesion that are not 
represented in the GSEA gene sets, but that may be important in promoting 
invasion in NCCIT cells.  (3) GSEA considers the gene set as a whole entity.  
While several members of the gene set may not be significantly enhanced, there 
still may be a few members of that gene set that are significantly altered in the 
shSKI NCCIT cells.  (4) The absence of significant changes in groups of genes 
such as MMPs may be explained by the fact that these genes may not be 
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transcriptionally regulated by SKI, but could possibly be altered at the level of 
protein activity.  MMPs are made as propeptides and require cleavage for 
activation (Fanjul-Fernandez, et al., 2009).  It is possible that decreased SKI 
expression my lead to the transcription of certain genes that promote the 
eventual cleavage and activation of MMPs.  Further studies could be performed 
to determine if the activity of certain MMPs is increased in SKI-knockdown 
NCCIT cells to assess whether the activation of MMPs plays a role in the 
enhanced invasive phenotype observed in SKI-deficient NCCIT cells.  These 
studies involve exposing the cells to gels containing the specific substrate for a 
particular MMP, and measuring the breakdown of that substrate.   
Although MMP expression was not significantly changed in shSKI 
compared to shNC NCCIT cells, the microarray data did show an increase in 
ADAMTS1, a metalloproteinase from another gene family, in shSKI NCCIT cells 
compared to shNC NCCIT cells, which was confirmed by real time PCR.  
ADAMTS1 is a member of the ADAMTS (A Disintegrin And Metalloproteinase 
with ThromboSpondin repeats) family.  This gene family is involved in proteolytic 
processing of transmembrane proteins, cell adhesion, and cell signaling 
(Mochizuki and Okada, 2007).  ADAMTS1 has been shown to be upregulated in 
cancers with advanced metastatic potential, including breast cancer (Kang, et al., 
2003) and pancreatic cancer (Masui, et al., 2001).  It has also been reported that 
ADAMTS1 forced overexpression in human lung carcinoma cells promotes tumor 
development and enhances tumor cell proliferation after injection in into SCID 
mice (Rocks, et al., 2008).  These data imply that increased ADAMTS1 
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expression may promote cancer progression.  However, more research is 
necessary to determine if ADAMTS1 expression is regulated by SKI and to 
delineate the role of ADAMTS1 in testicular cancer. 
The microarray data revealed several genes and gene families that are 
potential targets of SKI and/or may be involved in an enhanced metastatic 
phenotype in testicular cancer.  From the list of genes generated by the 
microarray analysis, a subset of genes associated with invasion, migration, or 
TGF superfamily signaling was chosen to assess whether their promoters 
contained SMAD binding elements.  These genes include ADAMTS1, CXCR4, 
FST, LEFTY1, MAP3K7, SMAD7, SPARC, and WNT3.  In addition, SMAD6 and 
MMP9 were used as controls.  The purpose of this assessment was to determine 
if these genes might be downstream signaling targets of either BMP or TGFβ.  
The presence of a SMAD binding element within the promoter region of these 
genes would indicate that the gene may be transcriptionally activated by BMP or 
TGFβ.  Although no true SMAD consensus sequence has yet emerged, a 
literature search revealed several potential SMAD 2/3 and SMAD1/5/8 binding 
sequences.  Genes containing binding sites for SMAD2/3 within their promoter 
region would potentially be activated in response to TGFβ signaling, while genes 
containing SMAD1/5/8 binding sites would potentially be activated by BMP.   
Since BMP treatment of SKI-knockdown cells resulted in an enhanced 
invasive phenotype, but TGFβ treatment did not elicit a response, we were 
interested in comparing the presence of BMP and TGFβ response elements in 
potential target genes identified through the microarray analysis.  The literature 
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search revealed that there is some overlap in the sequences that have been 
designated as BMP and TGFβ responsive.  In this analysis, three BMP-response 
elements and eight TGFβ-response elements were used.  However, 2 of the 
sequences, GTCTAGAC (Li, et al., 2001; Stopa, et al., 2000; Zawel, et al., 1998) 
and CAGACA (Dennler, et al., 1998; Jonk, et al., 1998; Katagiri, et al., 2002), 
have been described in the literature as being both BMP and TGFβ responsive.  
It was also reported that SMAD4 is able to bind to the sequence GTCTAGAC in 
the promoter of ID1 (Katagiri, et al., 2002), and this provides an explanation for 
the lack of specificity in regards to BMP and TGFβ responsiveness.  SMAD4 acts 
as the co-SMAD; it is able to form a complex with either BMP-induced 
SMAD1/5/8 or TGFβ-induced SMAD2/3 (Luo, 2003).  Therefore if the sequence 
GTCTAGAC is recognized by SMAD4, expression of genes with this element in 
their promoter could be activated by either BMP or TGFβ or both.  The third 
sequence, GCCGnCGC, has thus far been described to be specific to the BMP-
responsive SMADS (Benchabane and Wrana, 2003; Ishida, et al., 2000; Kim, et 
al., 1997; Kusanagi, et al., 2000). 
For the promoter analysis, SMAD6 was used as a positive control.  
SMAD6 was not differentially expressed in shSKI and shNC NCCIT cells, 
however, it has been reported that SMAD6 is BMP-responsive and contains the 
SMAD1 binding motif, GCCGnCGC (Ishida, et al., 2000).  The current analysis 
found the presence of multiple copies of the GCCGnCGC binding motif, as well 
as multiple copies of the two other BMP/TGFβ response elements, CAGACA and 
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GTCTAGAC.  This shows that the Motif locator tool was capable of recognizing 
the sequences.   
ADAMTS1, CXCR4, LEFTY1, SMAD7, MAP3K7, and WNT3 were all 
upregulated in SKI knockdown cells according to our microarray data.  CXCR4, 
SMAD7, and WNT3 promoters each contained all three of the BMP response 
elements, including the BMP-specific response element.  This suggests that their 
up-regulation in shSKI NCCIT cells may be due to increased BMP signaling.  In 
agreement with these data, SMAD7 has previously been shown to be responsive 
to BMP (Benchabane and Wrana, 2003).  Although CXCR4 does appear to 
contain these BMP response elements, the real time PCR data presented in this 
text (Figure 3.14) did not show up-regulation of CXCR4 in response to treatment 
of shSKI NCCIT cells with BMP4.  It is possible that the concentration of BMP4 
used in these experiments was not sufficient to induce transcription of CXCR4, 
and further experiments are needed to determine if different concentrations of 
BMP might elicit an increase in CXCR4 mRNA expression.  It is also possible 
that the induction caused by SKI-knockdown is already maximal.  To test this, 
cell lines with varying levels of SKI expression could be treated with BMP to 
determine if cells with intermediate SKI knockdown showed a response.  Real 
time PCR could also be done for SMAD7 and WNT3 to determine if their 
expression is increased in shSKI NCCIT cells upon treatment with BMP.   
LEFTY1 and MAP3K7 both contained multiple copies of the BMP-specific 
response element, GCCGnCGC, and the BMP/TGFβ response element, 
CAGACA, suggesting they also may be up-regulated by BMP and/ or TGFβ.  
 102
ADAMTS1 contained multiple copies of both of the BMP/TGFβ response 
elements, GTCTAGAC and CAGACA.  Additionally, ADAMTS1 was the only 
gene queried that contained one of the TGFβ-specific response elements, 
ACAGACAGACAC, further suggesting possible regulation by TGFβ.   
FST (follistatin) and SPARC (secreted protein acidic and rich in cysteine) 
were both down-regulated in shSKI compared to shNC NCCIT cells.  Yet both of 
these genes contained multiple copies of both BMP/TGFβ response elements, 
and FST also contained multiple copies of the BMP-specific response element, 
suggesting they also may be regulated by BMP.  The presence of BMP response 
elements within the promoters of these two down-regulated genes would not 
support the hypothesis that decreasing SKI expression in NCCIT cells confers 
increased BMP signaling and allows increased expression of BMP target genes.  
FST is a negative regulator of the TGFβ superfamily, primarily activin (Ogino, et 
al., 2008).  It has previously been shown to be regulated by SMAD3 through a 
SMAD binding element (Blount, et al., 2009), therefore, it may primarily be 
regulated by activin and may not be BMP responsive.  SPARC is involved in 
matrix remodeling and has been implicated in cancer progression and metastasis; 
however, SPARC’s role in tumorigenesis appears to be context and cell-type 
dependent as it appears to act as a tumor suppressor in some tissues (Arnold 
and Brekken, 2009).  SPARC’s role in testicular cancer has not been studied to 
date.  Since SPARC did not contain the BMP-specific response element, it may 
be regulated by TGFβ and not by BMP. It is also possible that there are inhibitors 
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of FST and SPARC transcription present in shSKI NCCIT cells that prevent their 
transcription despite the presence of SMAD binding elements within the promoter.   
Finally, MMP9 was also used for the promoter analysis.  According to the 
microarray data, MMP9 was not differentially expressed in shSKI and shNC 
NCCIT cells, and, therefore, does not appear to be responsive to SKI expression.  
However, the promoter analysis shows that the MMP9 promoter does contain 
both of the BMP/TGFβ response elements.  It does not contain the BMP-specific 
response element.  Again, it is possible that this gene may be regulated by TGFβ, 
which did not appear to have an effect in our system, and not by BMP.  Because 
two of the sequences used for this analysis have been described to be 
responsive to both BMP and TGFβ induced SMADs, it is somewhat difficult to 
draw a conclusion about the genes that have these two motifs in their promoters.  
They could potentially be activated by TGFβ or BMP or both.  The SMAD 
transcription factor complex requires several binding partners to activate 
transcription of target genes, and these binding partners account for some of the 
specificity between TGFβ and BMP activated transcription (Massague and 
Wotton, 2000).  Certain DNA binding cofactors, such as FAST (forkhead activin 
signal transducer), are specific to SMAD2/3-SMAD4 complexes, while others, 
such as OAZ (OLF1/EBF-associated zinc finger protein), bind to the BMP 
responsive SMAD complex, SMAD1/5/8-SMAD4 (Massague and Wotton, 2000).  
Therefore, future studies should focus on the identification of these binding 
factors to determine which are present in NCCIT cells and if potential target 
genes also contain motifs for these cofactors.   
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From this collection of data, a model for the acquisition of a more invasive 
phenotype in testicular cancer cells is proposed that involves reduced levels of 
SKI, which results in aberrant expression of both BMP-dependent and BMP-
independent downstream target genes (Figure 4.1).  In this model, a primitive 
germ cell acquires a mutation, such as protection from antiproliferative signaling, 
forming a precancerous cell.  This precancerous cell then undergoes additional 
transformation to gain the properties of a cancerous cell, including uncontrolled 
proliferation, evasion from apoptosis, and immortalization.  The acquisition of 
these properties results in the formation of an intratubular germ cell neoplasia, 
however further mutations are required for the ITGCN to invade the surrounding 
tissue.  The data presented within this text indicate that loss of function of SKI 
may promote this transition to a more invasive phenotype.  As shown in the 
model, loss of SKI expression results in uncontrolled BMP signaling as well as 
upregulation of other BMP-independent genes.  Uncontrolled BMP signaling 
allows increased expression of BMP target genes, some of which promote 
testicular cancer metastasis.  Additionally, loss of SKI expression promotes the 
expression of other genes, such as CXCR4, that promote testicular cancer 
metastasis.  According to this model, the increased expression of CXCR4 
promotes metastasis to distant sites where SDF1, the ligand for CXCR4, is 
expressed; these include the lymph nodes, lung, liver, and brain.  The changes in 
gene expression brought on by loss of SKI result in invasion of the surrounding 
lymph nodes by the cancerous cells and dissemination to distant organs.   
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The microarray data presented here indicates that loss of SKI expression 
enhances the expression of genes in other signaling families, such as the WNT 
and MAP kinase families, thus these signaling families may also be involved in 
promoting an invasive phenotype in testicular cancer cells.  For example, SKI 
has been shown to be a binding partner of FHL2, which can activate or repress 
β-catenin, depending on cell type (Chen, et al., 2003).  Therefore, decreased SKI 
expression could potentially result in lack of interaction with FHL2 and lack of 
repression of β-catenin in testicular cancer cells.  β-catenin has previously been 
correlated with an invasive phenotype in breast cancer (Niu, et al., 2009) and 
colon cancer (Suzuki, et al., 2008).  Further research on the interactions of these 
pathways in testicular cancer cells is necessary to determine their importance in 
testicular cancer metastasis.   
The data presented here provide further insight into testicular cancer by 
identifying SKI as a potential regulator of male germ cell tumor metastasis.  
These data show that testicular cancer cells with decreased SKI expression have 
a greater ability to invade and metastasize.  Furthermore, the data provide 
evidence that the BMP pathway plays a role in this process by further increasing 
the metastatic potential of SKI-deficient testicular cancer cells.  Noggin, a BMP 
inhibitor, was able to reverse the effects of BMP in SKI-knockdown NCCIT cells.  
This suggests that the BMP pathway may be a potential target for the 
development of new therapies to treat metastatic testicular cancer.  The use of 
noggin, or other small molecule inhibitors of BMP, may be useful in preventing 
progression of testicular cancer and warrants further research.   
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In accordance with previous findings (Gilbert, et al., 2009), these data 
confirm the importance of CXCR4 and SDF1 signaling partners in testicular 
cancer metastasis and also, for the first time, indicate that SKI may play a role 
regulating the expression of CXCR4.  This implicates CXCR4 and SDF1 as 
potential targets for therapies to treat testicular cancer metastasis as well.  In the 
current studies, AMD3100 was effective at blocking the effects of CXCR4/SDF1 
signaling partners, revealing AMD3100 as a candidate for the treatment of 
metastatic testicular germ cell tumors.  AMD3100 is a small molecule inhibitor 
that is highly specific for CXCR4 (Broxmeyer, et al., 2005; Hatse, et al., 2002) 
and has been used in clinical trials as an anti-HIV drug because CXCR4 is a co-
receptor used by HIV to enter T-lymphotropic cells (De Clercq, 2005; De Clercq, 
2009; Hendrix, et al., 2000).  In these trials, AMD3100 (Plerixafor) was very 
effective in inhibiting HIV-1 and HIV-2 viral replication.  While no toxicity was 
observed, the main side effect in patients treated with AMD3100 was 
leukocytosis, or increased white blood cells (De Clercq, 2005).  The discovery of 
this side effect led to clinical trials using AMD3100 as a hematopoetic stem cell 
mobilizer to treat patients with non-Hodgkins lymphoma and multiple myeloma 
(Stiff, et al., 2009).  These clinical trials have shown that AMD3100 is safe for use 
in humans, but further studies are necessary to determine the efficacy of this 
drug in the treatment of testicular cancer metastasis.   
Additionally, several potential targets of testicular cancer metastasis were 
revealed by microarray analysis.  These genes were up- or down-regulated in 
SKI-deficient NCCIT cells and further studies to elucidate the interaction between 
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these individual genes or signaling families and SKI will likely provide additional 
targets for the development of gene therapies.   
Previous studies have yielded conflicting roles for SKI in the metastatic 
process (Reed et al., 2001; Le Scolan et al., 2008; Zhu et al., 2008).  The studies 
presented within this text are the first to implicate SKI as regulator of metastasis 
in testicular cancer; this is in accordance with other studies showing that loss of 
SKI function promotes invasion in some types of cancer, including lung and 
breast (Le Scolan, et al., 2008; Zhu, et al., 2007).  However, other studies have 
shown that increased SKI expression correlates with cancer progression in 
melanoma cells (Reed, et al., 2001).  Taken together, these findings reveal that 
metastasis is a very complex process that depends upon the various signals 
present within the microenvironment of specific tissues that guide a cancerous 
cell to invade the basement membrane and metastasize to distant tissues.  When 
compared with previous data, it appears that SKI may function to promote tumor 
progression in some cell types, such as melanoma cells, but inhibit cancer 
metastasis in other cell types, such as testicular cancer cells.  Furthermore, the 
findings on CXCR4/SDF1, taken together with previous data (Gilbert, et al., 
2009), show that not only are the factors present within the microenvironment of 
the primary tumor important, but factors, such as SDF1, found in the sites of 
metastasis must also be considered when attempting to develop therapies for the 
treatment of malignant disease.   
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Figure 4.1.  Proposed mechanism for SKI’s role in testicular tumorigenesis.  A 
primitive male germ cell acquires a mutation, forming a precancerous cell.  This 
precancerous cell then undergoes transformation, gaining additional properties of a 
cancerous cell, to form an ITGCN.  Loss of SKI expression in ITGCN results in changes 
in gene expression, both BMP-dependent and BMP-independent, that contribute to an 
invasive phenotype, allowing the cancerous cells to invade the adjacent lymph nodes 
and disseminate.  Noggin is able to abrogate the effects of BMP in this model.  BMP-
independent changes in gene expression, including increased expression of CXCR4, 
further contributes to the metastatic potential.  CXCR4 interacts with its signaling partner 
SDF1, to promote metastasis to tissues expressing SDF1.  This interaction is inhibited 
by AMD3100. 
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 SUMMARY 
 
We have shown that SKI expression is reduced in human testicular germ 
cell tumors compared to normal human testis.  To our knowledge, this is the first 
study showing a decrease in SKI expression in testicular cancer.  Our studies 
have also shown that experimentally reducing SKI in a testicular cancer cell line, 
NCCIT, results in an increased ability of these cells to migrate and invade.  In 
parallel with this finding, forcing the overexpression of SKI in NCCIT cells 
resulted in a less invasive phenotype.  This data suggests that SKI may function 
as an inhibitor of metastasis in testicular cancer.   
Through a microarray study, we found that a large number of genes are 
differentially expressed in NCCIT cells stably transfected with a shRNA vector for 
SKI knockdown compared to NCCIT cells stably transfected with a negative 
control shRNA vector.  These differentially expressed genes are potential target 
genes of SKI that may be involved in the increased invasive phenotype of SKI-
deficient NCCIT cells.  Furthermore, we were able to identify the presence of 
BMP response elements within the promoter regions of certain genes, including 
ADAMTS1, CXCR4, LEFTY1, SMAD7, and WNT3, from the microarray, 
indicating that these genes are potentially upregulated by BMP signaling in SKI-
deficient NCCIT cells. 
We also found that TGFβ does not enhance migration in SKI-knockdown 
NCCIT cells.  However, BMP does enhance the migration of SKI-knockdown 
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NCCIT cells, and noggin, a BMP inhibitor, blocks the effect of BMP on SKI-
knockdown cells.  This indicates that decreased SKI expression in testicular 
cancer may confer increased sensitivity to BMP-receptor driven signaling, 
thereby enhancing the metastatic phenotype of these cells.  Furthermore, we 
found that CXCR4 expression is upregulated in SKI-knockdown cells.  CXCR4, 
and its signaling partner, SDF1, have previously been implicated in testicular 
cancer metastasis.  We found that the CXCR4/SDF1 signaling partners promoted 
invasion in SKI-deficient cells but not in cells that retained a higher level of SKI 
expression.  This indicates that the absence of SKI is an important factor in 
testicular cancer metastasis.  Furthermore, our data suggest that BMP and 
CXCR4/SDF1 signaling partners may be potential targets for therapies to treat 
patients with metastatic testicular cancer.  This is an area of research that 
warrants further investigation. 
The microarray data presented in this text also indicate that genes 
belonging to that the MAP kinase and WNT signaling pathways are up-regulated 
in SKI-deficient cells.  This suggests that these pathways may be regulated at 
some level by SKI expression.  Certain genes in these pathways may also be 
involved in promoting testicular cancer metastasis.  Studying the interaction 
between these pathways and the BMP pathway, and how SKI regulates their 
target gene expression will likely further shed light on the mechanisms behind 
male germ cell tumor metastasis and provide additional targets for testicular 
cancer therapies. 
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The data presented in this text identify SKI as a potential tumor 
suppressor of testicular cancer and provide a mechanism by which the increased 
invasive phenotype is acquired.  This allows a better understanding of the 
disease process involved in testicular tumorigenesis which may help with the 
development of treatments for patients with disseminated disease who have a 
worse prognosis.  As scientific advances are made that allow the development of 
therapies targeted more directly at the testicular cancer cells rather than targeting 
all rapidly dividing cells, as with chemotherapy and radiation, the patients’ quality 
of life will be enhanced through decreased side effects of cancer treatment. 
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FUTURE DIRECTIONS 
 
 The research presented in this text provides novel information regarding a 
possible mechanism by which testicular cancer cells acquire an increased ability 
to invade and metastasize.  However, more research is necessary to fully 
understand the role that SKI plays in testicular cancer.  Our data implicates SKI 
as a tumor suppressor of testicular cancer.  There are several mechanisms by 
which tumor suppressor activity is lost in cancer cells, such as gene silencing 
modifications to the promoter region, allelic loss due to chromosome instability, 
and DNA sequence mutation that leads to decreased gene expression or 
decreased protein activity.  Additional studies could be performed to determine 
the mechanism by which SKI expression is decreased in testicular germ cell 
tumors compared to normal testis.  This information is important because it would 
further support the role of SKI as a tumor suppressor, and it would allow a better 
understanding of testicular cancer progression.  
 Our data suggest that the BMP pathway is involved in the increased 
invasive phenotype seen in SKI knockdown NCCIT cells.  Further investigation 
into potential BMP target genes would help in understanding exactly how this 
pathway contributes to invasion in testicular cancer.  The microarray analysis 
provides a good starting point for looking into potential BMP target genes that 
may promote metastasis of testicular cancer.  Identification of these genes may 
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present new targets for testicular cancer therapies.  Determining the importance 
of SMAD signaling in the increased invasive phenotype observed in SKI-deficient 
testicular cancer cells would also provide an increased understanding of the 
importance of the BMP signaling pathway.  This could potentially be 
accomplished using siRNA against SMADs 1, 5, and 8 or dominant negative 
proteins to determine if SMAD-mediated transduction of BMP signaling is 
required for the increased ability of SKI-deficient cells to migrate. 
 In our studies, TGFβ did not affect the invasive potential of SKI-deficient 
cells.  In order to better understand why TGFβ does not function to enhance 
migration in SKI deficient cells, experiments could be done to identify if this lack 
of response is due to inhibitors of TGFβ blocking the signal or if some component 
of the TGFβ signaling pathway is not functioning properly.   
 Furthermore, several genes were shown to be differentially expressed by 
microarray analysis in shSKI NCCIT cells compared to shNC NCCIT cells.  This 
microarray analysis was performed on cells that were stably transfected for SKI 
knockdown or with a negative control vector; thus they do not confirm that loss of 
SKI directly controls the transcription of these genes.  Assays, such as lacz 
transcription assays, to determine the direct interaction of SKI with the potential 
target genes would provide a more detailed look at the exact pathways involved 
in testicular cancer progression.  Additionally, the importance of the upregulated 
target genes identified by microarray analysis in testicular cancer metastasis 
could be tested by using siRNA or dominant negative proteins to determine if 
they are required for increased invasive potential in SKI-knockdown NCCIT cells. 
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 Our experiments were performed using NCCIT cells, which are classified 
as embryonal carcinomas.  In reviewing the literature, it appeared that some 
gene expression profiles were specific to either embryonal carcinomas or 
seminomas.  Our data showed that SKI was decreased in various types of 
testicular germ cell tumors.  Thus, it would be interesting to know if decreased 
SKI expression had similar effects on seminoma cells as we saw in embryonal 
carcinoma cells.  
 Additional experiments studying the effects of the pathways outlined in this 
text in an in vivo model would be very beneficial in the clinical translation of this 
research to the development of gene-targeted testicular cancer therapies.  As 
mentioned, the data presented here suggest that BMP and the signaling partners, 
CXCR4/SDF1, promote invasion in SKI-deficient testicular cancer cells, 
potentially making these molecules attractive targets for the development of new 
treatments against metastatic testicular cancer.  First, the efficacy and safety of 
inhibitors of these pathways would need to be assessed using an in vivo model.  
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CHAPTER V 
 
METHODS 
Tumors 
 Testicular tumors and normal human testis tissues were provided by the 
Cooperative Human Tissue Network, which is funded by the National Cancer 
Institute. Other investigators may have received samples from these same 
tissues.  Tissues were frozen in liquid nitrogen and stored at -80C until analysis. 
Tumor and normal samples were analyzed for relative gene expression after 
laser capture microdissection as described below. 
 
Laser Capture Microdissection 
 Normal and tumor tissue specimens were embedded in Tissue-Tek OCT 
(VWR, Batavia, IL) medium for frozen sectioning.  Five-micrometer sections were 
processed with the Arcturus HistoGene kit (Molecular Devices, Sunnyvale, CA).  
Sections were briefly fixed and dehydrated in ethanol, stained with hematoxylin 
and dried in xylene prior to sample capture using the Arcturus Pixcel IIe 
(Molecular Devices, Sunnyvale, CA).  Tissue captured from normal testes 
included seminiferous tubules, but not interstitial cells. Tumor cells were isolated 
avoiding stromal elements.  After capture the samples were extracted for RNA 
using the RNeasy Micro Kit (Qiagen, Valencia, CA).  RNA quantity and integrity 
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were assessed using the 2100 Bioanalyzer and the RNA Pico Kit (Agilent 
Technologies, Santa Clara, CA). 
 
Cell Culture 
NCCIT cells were purchased from American Type Culture Collection 
(Manassas, VA).  NCCIT cells were cultured in RPMI 1640 (Invitrogen, Carlsbad, 
CA) supplemented with 10% fetal bovine serum (FBS; Invitrogen, Carlsbad, CA) 
and 1% penicillin-streptomycin (Invitrogen, Carlsbad, CA).  Cells were grown in a 
humidified atmosphere containing 5% CO2 at 37°C. 
 
Materials 
TGFβ, TGFβ blocking antibody, BMP4, noggin, and SDF1 were purchased 
from R & D Systems (Minneapolis, MN).  AMD3100 was purchased from 
SigmaAldrich (St. Louis, MO). 
 
Transient siRNA Transfections 
For transfection protocols, NCCIT cells were plated in antibiotic-free RPMI 
medium, and, on the day of transfection, the medium was changed to Opti-MEM 
Reduced Serum Medium (Invitrogen, Carlsbad, CA) supplemented with 2% FBS.  
For siRNA knockdown of SKI, three individual siRNAs specific to SKI and a non-
specific control siRNA were purchased from Invitrogen.  Cells were plated in 6 
well plates at 5x105 cells/well.  Twenty-four hours after plating, when the cells 
were approximately 60-70% confluent, the cells were transfected with one of the 
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three SKI siRNAs or the non-specific control siRNA at a final concentration of 20 
μM siRNA.  Mock transfections, using Lipofectamine 2000 transfection reagent 
(Invitrogen, Carlsbad, CA), were performed to ensure that there were no adverse 
consequences from the transfection procedure.  Transfection efficiency was 
assessed both visually and through the use of flow cytometry on cells transfected 
with Block-It (Figure 5.1), a fluorescently tagged oligonucleotide, as described by 
the manufacturer (Invitrogen, Carlsbad, CA).  Transfection efficiencies were 
routinely greater than 80%.  Knockdown of SKI mRNA and protein levels were 
assessed at 24, 48, and 72 hrs, using real time PCR and western blotting, 
respectively. 
 
Flow Cytometry 
Cell culture medium was aspirated from cells, and the cells were washed 
with PBS prior to collection via trypsinization.  Cells were spun down, washed 
with PBS, and resuspended in 1% paraformaldehyde/PBS solution.  Ten 
thousand events were analyzed using the BD FACSaria with the FITC-A laser.  
To determine the transfection efficiency, the percentage of cells positive for 
FITC-A was determined using BD FACSDiva software.   
 
SKI Expression Vector Transient Transfection of NCCIT Cells 
To force the expression of SKI in NCCIT cells, a SKI expression vector, 
generously donated by Dr. Estella Medrano, Baylor College of Medicine, was 
transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA), according to 
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the manufacturer’s protocol.  Briefly, NCCIT cells were plated in 6 well plates at 
5x105 cells/well in medium without antibiotics.  Twenty four hours after plating, 
the medium was replaced with OptiMEM supplemented with 2% FBS, and the 
cells were transfected with 5μg of either the SKI expression vector or the empty 
vector (Invitrogen).  SKI mRNA and protein levels were assessed at 24, 48, and 
72 hours by Real Time PCR and western blotting, respectively. 
 
Generation of Stably Transfected SKI-knockdown NCCIT cells 
NCCIT cells were plated at 3.5X105 in antibiotic-free medium, and, on the 
day of transfection, the medium was changed to Opti-MEM Reduced Serum 
Medium (Invitrogen, Carlsbad, CA) supplemented with 2% FBS.  Transfections 
were performed on cells that had been passaged less than 5 times.  Pre-
designed SureSilencingTM shRNA vectors specific to SKI (shSKI) and an shRNA 
negative control vector (shNC) were purchased from SuperArray Bioscience 
Corporation (Frederick, MD).  The cells were transfected using Lipofectamine 
2000 transfection reagent (Invitrogen, Carlsbad, CA), according to 
manufacturer’s suggestions.  Transfected cells were selected using 600 µg/mL 
Geneticin because the shRNA vectors contained a neomycin-resistance gene.  
Clones were established from single cells and were analyzed for SKI expression 
via Real Time PCR and western blotting.  Stably transfected NCCIT cells were 
cultured in RPMI 1640, supplemented with 10% FBS and 300 µg/mL Geneticin 
(Invitrogen, Carlsbad, CA).  Stably transfected NCCIT cells are denoted 
shNCCIT as a group.  NCCIT cells stably transfected with the negative control 
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Figure 5.1.  Transfection efficiency assessed by Block-It transfection.  NCCIT cells 
transfected with Block-It were assessed both visually and by flow cytometry for 
transfection efficiency.  (A) Microscopic assessment of NCCIT cells transfected with 
Block-It.  (B)  Flow cytometry analysis of NCCIT cells transfected with Block-It.  (C)  
Microscopic assessment of NCCIT cells mock-transfected with lipofectamine 2000.  (D)  
Flow cytometry analysis of NCCIT cells mock-transfected with lipofectamine 2000.   
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shRNA vector are denoted shNC NCCIT, and NCCIT cells stably transfected with 
the SKI shRNA vector are denoted shSKI NCCIT.  SKI knockdown was routinely 
assessed via real time PCR and western blotting.   
 
Real Time PCR 
Total RNA was extracted from NCCIT cells using TRIzol (Invitrogen, 
Carlsbad, CA).  Relative levels of gene expression were measured by real-time 
polymerase chain reaction (PCR) using Taqman probes and the 7000 
Sequence Detection System (Applied Biosystems, Foster City, CA).  First strand 
cDNA was synthesized from 2 ng total RNA using Superscript III reverse 
transcriptase (Invitrogen, Carlsbad, CA).  Taqman probes for SKI, SNO, CCND2 
LFT1, ADAMTS1, and CXCR4, SDF1, and 18S ribosomal RNA were purchased 
from Applied Biosystems (Foster City, CA).  Probes for 18S ribosomal RNA were 
used as the endogenous control.  Relative expression levels for SKI, SNO, 
CCND2 LFT1, ADAMTS1, and CXCR4, SDF1 were calculated using the 2-Ct 
method (Livak and Schmittgen, 2001).  Data for the tumor samples were 
normalized to the endogenous control and to the normal tissues.  Data for siRNA 
treated cell lines were normalized to the endogenous control and to cells 
transfected with the non-specific control siRNA. 
 
Western Blotting 
Protein was extracted from NCCIT, N-TERA2/D1 (NT2/D1), HepG2, 
HMEC, MCF7, T47D, A549, SbCl2, WM1366, WM9, HCT116, SK-N-AS, and SK-
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N-SH cells with lysis buffer containing 50mM Tris, 150mM NaCl, and 0.1% 
IGEPAL (Cobb, et al., 1997). Total protein concentration was determined by 
Bradford assay. Twenty micrograms of total protein lysate were run on a 10% 
SDS-PAGE gel (BioRad, Hercules, CA) and transferred to a nitrocellulose 
membrane.  Successful transfer of the protein was assessed by staining the blots 
with Ponceau S (Sigma Aldrich, Saint Louis, MO), and then the stain was 
washed off with distilled water.  Membranes were blocked in a 5% powdered 
milk/ PBS-Tween (0.5% Tween) (PBST) solution at room temperature for 1hr.  
SKI and α-tubulin antibodies were purchased from Millipore/Upstate 
(Charlottesville, VA).  SMAD2, p-SMAD2, SMAD 1/5, and p-SMAD 1/5/8 
antibodies were purchased from Cell Signaling Technologies (Danvers, MA).  
Blots were incubated in a primary antibody (Millipore/Upstate, Charlottesville, VA) 
overnight at 4°C at the following dilutions:  SKI 1:2000; SMAD2 1:1000, p-
SMAD2 1:1000, SMAD1/5 1:1000, and p-SMAD1/5/8 1:10,000.  SKI and α-
tubulin blots were incubated in a 1:20,000 dilution of the appropriate HRP-
conjugated secondary antibody (Pierce, Rockford, IL) at room temperature for 
one hour.  SMAD and p-SMAD blots were incubated in a 1:2000 dilution of anti-
rabbit IgG secondary antibody (Cell Signaling Technology, Danvers, MA) at room 
temperature for one hour.  α-tubulin was used as a loading control for 
densitometry; blots were reprobed with α-tubulin diluted at 1:10,000 at room 
temperature for 10 minutes, and then secondary antibody (rabbit-anti-mouse) at 
1:40,000 at room temperature for 10 minutes (personal communication with Dr. 
Beverly Delidow, Marshall University).  After primary and secondary antibody 
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incubations, the blots were washed 4 X 5 minutes. in PBST.  ECL Plus 
chemiluminescent reagent (GE Healthcare) was used for detection of the 
antibody as described by the manufacturer.   
 
Cell Scrape Migration Assays 
NCCIT cells were plated on Matrigel-coated cell culture plates and treated 
with either siRNA or the expression vector as described.  Forty-eight hours after 
siRNA transfection, when the cells were ≥ 90% confluent, a 20 μL pipette tip was 
used to create a scratch across the cell monolayer.  shNCCIT cells were plated 
and scraped in the same manner.  shNCCIT cells were treated with ± TGFβ (0.1 
nM), ±TGFβ blocking antibody (200 nM), or ± BMP4 (10 ng/mL), ± noggin (0.1 
µg/mL).  The cells were observed over a 20 hour time period, and images were 
taken of three fields of view per well at 0 hour and 20 hour using a Nikon inverted 
microscope (model Eclipse TS100-F) with camera attachment (Nikon Digital 
Sight DS-5M).  To ensure that the same fields were analyzed at 0 and 20 hours, 
identifying marks were made on the bottom surface of the well.  The percent 
closure of the scrape was determined by measuring the mean distance between 
the edges of the scrape (33 measurements per image; 99 measurements per 
well) at 0 and 20 hours using Image J 1.37v Analysis Software (Wayne Rasband, 
National Institutes of Health, USA, http://rsb.info.nih.gov/ij/).  The percent closure 
of the scrape was estimated by comparing the measurements at 20 hours to the 
measurements at 0 hours.  Treatments were performed in triplicate, and 
experiments were repeated at least three times (n=9). 
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 Matrigel Invasion Assays 
Forty eight hours after treatment with either siRNA or the expression 
vector, NCCIT cells were removed from the 6 well plates with trypsin, washed, 
and resuspended in 1 mL of serum-free Opti-MEM, and plated at 5x105 cells per 
Matrigel-coated invasion chamber inserts (Falcon cell culture inserts with an 8 
micron pore size PET membrane; BD Biosciences, Bedford, MA), containing a 
total volume of 2 mL serum-free Opti-MEM.  The inserts were held in 6-well 
companion plates, which contained 2.5 mL Opti-MEM with 2% serum (BD 
Biosciences, Bedford, MA).  According to the manufacturer’s protocol, after a 22 
hour incubation in the Matrigel invasion chambers, the cells were fixed to the 
membranes and stained using the Diff-Quik Stain Set (Dade Behring, Newark, 
DE), and the number of migrated cells was determined and compared to the non-
specific control siRNA-treated cells.  For each well, the number of invading cells 
was counted using Image J Analysis Software 1.37v in six random fields in each 
of three wells per treatment, and these numbers were added to obtain the total 
number of invaded cells for each sample.  Each treatment was performed in 
triplicate, and each experiment was performed three times. 
Stably transfected shNCCIT cells were plated at 5x105 in Matrigel-coated 
invasion chamber inserts in the 6-well companion plates, which contained 
OptiMEM supplemented with 2% FBS ± SDF1 (25 ng/mL), ± AMD3100 (50 
ng/mL).  
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Microarray Gene Analysis 
 Stably transfected shSKI and shNC NCCIT cells were plated on Matrigel-
coated 6-well plates and scraped as described for Matrigel cell scrape assays.  
Seventy two hours after plating, the cells were washed with PBS and collected 
using TRIzol (Invitrogen, Carlsbad, CA).  Six experiments were performed with 
three replicates in each experiment.  The three replicates from each experiment 
were pooled for the microarray analysis for a total of six shNC and six shSKI 
samples.  The samples were given to the Microarray Core Facility at Marshall 
University, Joan C. Edwards School of Medicine in TRIzol solution.  RNA 
extraction, microarray analysis, and statistical analysis on the microarray data 
were performed by the Microarray Core Facility at Marshall University, Joan C. 
Edwards School of Medicine.  Total RNA quality was determined using a Model 
2100 bioanalyzer (Agilent, Santa Clara, CA).  All samples had an RNA integrity 
number (RIN) greater than 8.  Six biological replicates were used in reference 
microarray design; sample cDNA is hybridized against cDNA derived from 
universal reference RNA (Stratagene/Agilent, Cedar Creek, Texas).  250 ng of 
total RNA was used for labeling with the QuickAmp labeling kit (Agilent) and Cy3-
CTP and Cy5-CTP from Perkin Elmer as previously described (Syed and 
Threadgill, 2006).  ShNC or shSKI samples were labeled with Cy3-CTP, and 
universal human reference RNA (Agilent, Santa Clara, CA) was labeled with 
Cy5-CTP.  Following purification of labeled cRNA, 825 ng of Cy3 and Cy5-
labeled sample were combined and hybridized on a microarray chip containing 
45,016 features that represent 33,000 known and novel human genomes for 17 
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hours at 65°C in an Agilent hybridization oven.  Slides containing arrays were 
then washed and scanned using the Agilent DNA microarray scanner.  Intensity 
of microarray features was measured using Agilent Feature Extraction software 
(version 9.5).  Extracted data was lowess normalized.   
Statistical analysis of microarray (SAM) and gene set enrichment analysis 
(GSEA) (http://www.broadinstitute.org/gsea) were used to identify significant 
genes and gene families that were differentially expressed in shSKI NCCIT cells 
compared to shNC NCCIT cells.  SAM was used to determine significant 
changes in the expression of individual genes in shSKI cells compared to shNC 
cells.  The cutoff for differential expression was a 1.5 fold change.   
 The GSEA software version 2.0.4 (Subramanian, et al., 2005) from the 
BROAD Institute (http://www.broadinstitute.org/gsea) was used to perform gene 
set enrichment analysis.  This analysis was used to compare SKI-knockdown, 
shSKI NCCIT cells, to control cells, shNC NCCIT cells, to identify specific gene 
sets enriched in the shSKI phenotype.  The dataset queried consisted of 26,712 
genes.  The GSEA software is designed to filter out gene sets containing less 
than 15 or more than 500 genes, which resulted in 586 gene sets to be used in 
the analysis.  380 out of the 586 gene sets were enriched in the shSKI NCCIT 
cells.  Of these 380, 147 gene sets met the criteria of a false discovery rate (FDR) 
less than 0.25, and 101 of these gene sets were significantly enriched at a 
nominal p-value less than 0.05.  The familywise-error rate (FWER) is a more 
conservative correction that ensures that the results reported do no contain a 
single false-positive gene set (Subramanian, et al., 2005); using the more 
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stringent cutoff of FWER less than 0.05 resulted in only a few enriched gene 
families in shSKI NCCIT cells.   
 
Promoter Analysis 
 The Motif Locator tool on the MOtif Discovery (MoD) tools website 
(http://159.149.109.9/modtools/) (Pavesi, et al., 2006) was used to determine if 
potential target genes of SKI that were identified by microarray analysis 
contained SMAD binding elements.  BMP and TGFβ SMAD binding elements 
were chosen via a literature search.  The following SMAD binding sequences 
were used:  BMP elements:  GTCTAGAC, (Li, et al., 2001; Zawel, et al., 1998); 
CAGACA (Dennler, et al., 1998; Jonk, et al., 1998); GCCGnCGC (Kusanagi 2000, 
Ishida 2000, Kim 1997, Benchabane 2003); TGFβ elements:  GTCTAGAC 
(Stopa 2000); AG(C/A)CAGACA (Dennler, et al., 1998; Jonk, et al., 1998); 
AGACAAGGTTGT (Song, et al., 1998); ACAGACAGACAC (Wong, et al., 1999); 
GCCCACCAGACAGATGGCTGAATCACAGGAGTGGCCGGCGGGACCCATGG
CCT (Kon, et al., 1999; Vindevoghel, et al., 1998); 
AGACAGACAAAACCTAGACAATCACGTG 
GCTGGCTGCATGCCCTGTGGCTGTTGGGC (Hua, et al., 1998); 
CCTAGACAGACAA AACCTAGACAATCACGTGGCTGG (Hua, et al., 1998; Hua, 
et al., 1999); GAGGAGGTAGAC AGACAGCTATGT (Lindemann, et al., 2001); 
AGTATGTCTAGACTGA (Shi, et al., 1998).  Two of the sequences used have 
been described to be both BMP and TGFβ response sequences.  In this analysis, 
one substitution in the binding element sequence was allowed.  The default 
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minimum match percent of 85% was chosen to report motif matches, and both of 
the complementary strands of the input promoter sequences were searched.   
Promoter sequences were obtained from the Transcriptional Regulatory 
Element Database (TRED; http://rulai.cshl.edu/cgi-
bin/TRED/tred.cgi?process=searchPromForm) developed by Michael Zhang’s 
laboratory at Cold Spring Harbor.  The promoter sequences used spanned from -
3000 to +300, and the following genes were searched for SMAD binding 
elements:  ADAMTS1, CXCR4, LEFTY1, SMAD7, SMAD6, WNT3, FST, SPARC, 
and MMP9.   
 
Statistical Analysis 
Data are reported as the mean of at least three individual experiments, 
and error bars represent standard error of the mean, except for the real-time 
PCR analysis for which error bars represent the 95% confidence intervals.  Data 
were analyzed for significance with SigmaStat using a One Way Analysis of 
Variance (ANOVA) with Bonferroni adjustment, T-test, or Two-Way ANOVA.  For 
the Two-Way ANOVA tests, all pairwise multiple comparison procedures were 
assessed for significance with a Tukey test.  Significance was assessed at the p 
< 0.05 level. 
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